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GENERAL INTRODUCTION
Phenotyping based on profiling of small molecules
Phenotyping based on molecular profiling is a type of screening which investigates the 
phenotype of a biological system such as cells, tissues or whole organisms. The phenotype 
is a description of the total of physical characteristics of a biological system including its 
morphology, development, but also its biochemical properties. Profiling the phenotype is 
interesting since phenotypic effects can be induced by various (biological) perturbations such 
as a disease, drug interventions and genetic alterations. Phenotyping based on the profiling 
of small molecules such as metabolites can provide important insights into e.g. disease and 
the effect of drugs, as well as a systems understanding of the ability to adapt and cope with a 
perturbation[1].
For the profiling of small molecules there are different techniques available. There is often 
an inverse relation between assay comprehensiveness (analyte coverage) and the throughput 
of the assay (see Figure 1). Whereas a single analyte high-throughput screen (HTS), such as 
microscopy assays, enzyme-linked immunosorbent essays (ELISA) or fluorescence-activated 
cell sorting (FACS) can screen over a million compounds per week, comprehensive mass 
spectrometry (MS)-based assays which can potentially screen for hundreds of analytes, 
are generally much slower [2]. As a consequence, comprehensive profiling assays have the 
potential to provide more in-depth information about the phenotype of a specific biological 
system than a single read-out biochemical assay. Therefore, in choosing the appropriate 
profiling technology, the balance between assay throughput and analytical comprehensiveness 
should be considered carefully with probably in many cases preferably maximal depth at high 
sample throughput.
Many conventional HTS approaches rely on fluorescent- or radio-labeling since these labels 
can be rapidly detected with high sensitivity [3]. Label-free strategies, including MS, have 
gained wide interest, since they can be applied to a broader range of assays and target classes. 
Moreover, MS-based screening is a comprehensive, selective and sensitive analytical tool 
which is not susceptible to the limitations imposed by labelling and coupling enzymes[4]. As 
a consequence, profiling of small molecules by MS has the potential to be a very powerfull 
technique. 
Mass Spectrometry
MS is a key analytical tool for detecting and identifying small (bio) molecules. Therefore 
in many bio-analytical applications MS has become a powerful quantitative and qualitative 
analytical technique. A MS comprises i) an ion source, where gas-phase ions (positively-
or negatively charged) are formed, ii) a mass analyser for separation of ions based on their 
mass-to-charge ratio (m/z) and iii) a detector, where arriving ions are detected.  A variety of 
different MS instruments are available, including high resolution (HR) MS such as fourier 
transform ion cyclotron resonance (FTICR), Orbitrap FT and time-of-flight (TOF) and low 
resolution MS such as ion traps and triple quadrupole systems. Among several available 
ionization techniques such as electron impact (EI), desorption electrospray ionization (DESI) 
and matrix-assisted laser desorption/ionization (MALDI), electrospray ionization (ESI) and 
atmospheric pressure chemical ionization (APCI) are predominantly used. MALDI and DESI 
techniques have recently attracted interest in the field of imaging MS (IMS). IMS involves 
comprehensive profiling of biological molecules by directly ‘scanning’ the analytes from a cell 
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Figure 1: Schematic picture representing the comprehensiveness of the small molecule assay versus the sample 
throughput of the assay. Assays with potential hundreds of read-out variables such as MS are oft en much slower than 
other single variable read-out assays, such as microscopy assays, enzyme-linked immunosorbent assays (ELISA) or 
fl uorescence-activated cell sorting (FACS).
Figure 2: Schematic picture depicting the inherent trade-off  between the quantitative power of a MS-based platform 
and its sample throughput.
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distribution patterns of the analytes. IMS techniques can in principle be very fast, especially 
when only one spot per sample needs to be analyzed. Moreover, when employing e.g. DESI, 
limited or even no sample pretreatment is necessary. As a consequence, IMS has become a 
rapid and valuable tool across many fields, yet its major challenge is to acquire quantitative 
data regarding the surface concentrations of the analytes[5].
The developments in (HR)MS instruments have drastically increased ion selectivity for 
obtaining high resolution and moreover, enabled the detection of minute amounts of analyte 
(femtograms)[6]. However, one of the disadvantages of a MS is its limited dynamic range 
which is at best five orders of magnitude. More importantly, when using ESI, potential analyte 
competition during ionisation in the ion source, called ion suppression, imposes challenges in 
order to obtain quantitative results[7]. The same is true for most other ionization techniques.
As a consequence, prior to MS detection, several separation techniques are often employed 
such as liquid chromatography (LC)-MS, gas chromatography (GC)-MS or capillary 
electrophoresis (CE)-MS in order to reduce the amount of potential co-eluting ions in the ion 
source and therefore reduce potential ion suppression effects.  These hyphenated platforms 
can provide quantitative data, however at the expense of sample throughput (Figure 2).
Direct infusion-MS (DI-MS) is a fast and comprehensive analytical method in which a sample 
is introduced into the MS without prior separation, possibly after sample pretreatment. In 
DI-MS, samples can be introduced into the MS in several ways: (i) manually, by means of a 
syringe pump, or (ii) automated. Flow injection analysis-MS is a commonly used automated 
DI-MS approach which involves the injection of an analyte plug (typically a few microliters) 
into a flowing solvent stream by employing e.g. a LC autosampler and pump, omitting a 
chromatographic column[8]. Additionally, automated nanoESI robots are available which can 
directly introduce a sample into the MS through a small nanoESI microchip-nozzle (typically 
5 µm), in a ‘carryover-free’ manner[9]. However, although DI-MS can be fast and enables 
high-throughput analysis, it is often prone to ion suppression due to co-eluting ions such as 
(endogenous) salts and it is often not possible to differentiate between isomers. By employing 
nanoelectrospray (nanoESI) instead of conventional ESI, ionization efficiency can be increased 
and ion suppression can be reduced [10]. As a consequence, effective sample pretreatment is 
a key step prior to DI-MS analysis in order to obtain quantitative data[6]. When samples are 
effectively purified and the extracted analyte is within the dynamic range of the MS, analytical 
performance of DI-MS should be comparable with hyphenated MS platforms. As discussed, 
MALDI and DESI-MS are in principle faster per sample point than DI-MS as they can faster 
acquire MS spectra per sample. When e.g. using chip-based nanoESI-DI-MS, after every 
sample the nozzle has to be changed in order to prevent carry over, which will usually take a 
few seconds.
Sample pretreatment
A typical MS-based analytical workflow comprises sampling, sample pretreatment and MS 
analysis. Many MS-based methods require proper sample pretreatment procedures in order 
to overcome the mismatch of the sample with the analytical method. The sample pretreatment 
procedure should allow the reproducible enrichment/extraction of the analytes so that the 
concentrations are within the linear range of the MS. Moreover, depending on the analytical 
MS-platform, interfering molecules such as proteins and salts should be removed in order 
to maintain the integrity of the system and to reduce ion suppression and poor detection 
sensitivity. Furthermore, sample pretreatment is required to release the analytes of interest 
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subsequent analysis with the analytical instrument. However, MS-based methods have the 
drawback that they often require tedious protocols for sample pretreatment that decrease 
the throughput of the assay. Therefore, to achieve high-throughput automated and integrated 
analytical systems have to be developed which include the sample pretreatment procedure. 
Although these goals can partly be met by traditional methods, new concepts are required 
which simplify sample pretreatment and maintain robustness and a high-throughput capacity. 
Additionally, when sample volume is limited, miniaturization of the sampling as well as the 
sample pretreatment procedure is needed which can also potentially lead to the concept of 
massive parallelization.
Metabolomics 
The metabolome is the whole set of small molecules (typically <1000 Da) in a given biological 
sample. It can provide a functional readout of cellular biochemistry and therefore has the 
strongest correlation with the phenotype[1]. Therefore, metabolomics offers a promising 
phenotyping platform which has the potential to e.g. discover biomarkers for the diagnosis 
and prognosis of diseases and the prediction of the efficacy of drug interventions[11]
[12]. Metabolites are a highly diverse range of molecules with vast differences in chemical 
structure, physicochemical properties and dynamic range (up to nine decades[13][14]). 
As a consequence, metabolomics may be the most challenging phenotyping omics science. 
Whereas genomics and transcriptomics can amplify DNA sequences using polymerase chain 
reaction (PCR), in metabolomics there is no effective method which can ‘amplify’ all low-
abundant metabolites in an unbiased manner.
The metabolome can be considered as to the largest part a regulated dynamic phenotype in 
which changes in metabolite levels can e.g. reflect a transition from a healthy to a diseased 
state or the resilience of a system, in the context of systems homeostasis and allostasis. For the 
discovery of metabolic profiles to predict disease progression or the effect of interventions at 
an individual level, performing longitudinal studies is key in monitoring individuals which 
may result in personalized biology and eventually personalized medicine. For this strategy, 
following individuals over years will require high-throughput metabolomics approaches[1]. 
In addition, due to the vast biological variability of individuals, many individual samples may 
be analysed in a metabolomics study in order to ensure statistically meaningful results. As a 
consequence, such metabolomics studies should be performed preferably in a HT manner. In 
addition, each study should not only be carried out to analyse more samples within a period 
of time, but also to quantify as many relevant metabolites as possible in a single analysis, for 
which MS is in principle very suitable[15]. 
Aim and outline of the thesis
The aim of this thesis is to develop new methods for the mass spectrometry (MS)-based high-
throughput profiling of small molecules. Direct infusion (DI)-MS can potentially provide 
high-content and high-throughput analyses, but effective and rapid sample pretreatment 
procedures are needed in order to obtain enough quantitative performance, i.e. precision and 
accuracy, in the mass spectrometric analysis while maintaining assay throughput. Moreover, 
when the analysis of small sample volumes is required, new miniaturized concepts in sampling 
Chapter 1
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as well as sample pretreatment are needed. In addition, miniaturization of the experimental 
setup can play an important aspect with regards to the potential of massive parallelization 
and, consequently, can tremendously increase sample throughput.  
In Chapter 2 an overview of recent developments in sample pretreatment procedures for MS-
based metabolomics is given. Deproteinization, removal of interfering molecules, liquid-liquid 
extraction (LLE), solid-phase extraction (SPE), electromigration-based extraction methods 
and possibly emerging sample pretreatment techniques for metabolomics are described and 
discussed. Advantages and limitations of these techniques for metabolomics are given, and 
aspects such as potential for automation and high-throughput analysis are evaluated
In Chapter 3 the potential of nanoESI-DI-High Resolution-MS for the metabolic phenotyping 
of early zebrafish embryogenesis is investigated. It is studied whether efficient but limited 
sample pretreatment is sufficient to obtain metabolic profiles to distinguish early developmental 
stages during zebrafish embryos embryogenesis. Reproducible and high-quality MS data is 
generated by implementing an automated data-processing tool, which includes data clean-up 
steps and a dedicated normalization-optimization algorithm. Principle component analysis 
reveals that periods of 1 hour time shifts post fertilization can be differentiated from each 
other.
In Chapter 4, a new and fast and selective electromigration-based sample enrichment and 
purification technique called 3-phase electroextraction (3-phase EE) is presented and coupled 
to nanoESI-DI-MS. The electromigration of analytes from an aqueous sample through an 
immiscible organic filter phase into a small-volume aqueous acceptor phase is demonstrated. 
It is shown that selectivity of 3-phase EE can be tuned by changing the composition of the 
organic filter phase which also prevents proteins from migrating into the acceptor phase. 
Proof of principle towards online 3-phase EE-nanoESI-DI-MS is demonstrated and thus the 
compatibility of 3-phase EE with HTS is shown.
In Chapter 5 a proof of principle of a new miniaturized LLE technique in a 384-well plate 
is presented, based on gas pressure mixing followed by passive phase separation. This fully-
automated approach is integrated online into a nanoESI-DI-MS robot. It is shown that this 
high-throughput platform is suitable for screening drugs from human plasma with similar or 
better analytical performance compared to a conventional LLE procedure. Finally, the micro 
LLE method applied to dried blood spots is demonstrated.
In Chapter 6, a miniaturized sampling technique based on microneedle sampling is 
developed in order to monitor drug uptake in the (small-volume) yolk of zebrafish larvae 
using MS analysis. It is demonstrated that conventional whole zebrafish embryo lysis is not 
suitable for measuring drug uptake, due to potential adherence of drugs to the skin. The in 
vivo uptake MS-data is correlated to the results of in vitro and in vivo high-throughput drug 
screening platforms and it was shown that this new approach can give relevant information 
for interpretation of drug efficacy data.
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ABSTRACT
Metabolomics is one of the most rapidly evolving of the omics sciences. For phenotyping 
individuals, it offers a promising platform that is needed for breakthroughs in biomedical 
and pharmacological research. A proper sample-pretreatment procedure is required for 
metabolomics studies to overcome the mismatch of the sample with the analytical method. 
Within the analytical workfl ow for metabolomics studies, sample pretreatment is important 
in order to obtain the meaningful, high-quality quantitative data needed to minimize 
inconsistencies between laboratories. In this review, we provide an overview of state-of-the-
art sample-pretreatment techniques for mass spectrometry-based metabolomics. We pay 
attention to deproteinization, removal of interfering molecules, liquid-liquid extraction, solid-
phase extraction, electromigration-based extraction methods and possibly emerging sample-
pretreatment techniques for metabolomics. We give the advantages and the limitations of 
these techniques for metabolomics, and consider aspects such as automation and high-
throughput analysis. Finally, we provide some conclusions and perspectives.
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INTRODUCTION
Metabolites are key regulators of system homeostasis and provide a functional readout of 
cellular biochemistry. Metabolomics can be defi ned as a comprehensive analytical approach 
for the study of the complete set of metabolites (metabolome), present in a biological 
system[1]. Interest in metabolomics is rapidly expanding in various research fi elds, such as 
cancer research[2], drug discovery and development[3], toxicological, biomedical and clinical 
research and nutritional research. Th e major aim of metabolomics is to obtain an answer or 
insight to a biological question. An analytical workfl ow comprised of experimental design, 
sampling, sample pretreatment, data acquisition and data analysis is generally used to address 
a biological question by a metabolomics approach (Figure 1).
Within the analytical workfl ow for metabolomics studies, sample pretreatment is a key step 
as it has a major infl uence on both the overall coverage and quality of the obtained metabolic 
profi les and biological interpretation of the data. As such, it may be considered the most 
error-prone and time-consuming step of metabolomics studies and is maybe the major source 
of inconsistencies between laboratories[4]. 
Although technical advances have been made in the fi elds of bioanalysis and metabolomics in 
terms of automation and high-throughput analysis, a signifi cant part of the sample pretreatment 
procedure is still carried out manually[5]. Th e main challenges of sample pretreatment in 
metabolomics is the great diversity of chemical structures and physicochemical properties 
as well as vast diff erences in dynamic range (up to 9 decades) of the metabolites present in a 
biological sample[6],[7] and at the same time the lack of universal analytical comprehensive 
techniques with a suffi  cient dynamic range and physicochemical coverage. To ensure that 
the measured metabolic profi les are representative, the sample pretreatment procedures used 
should allow the reproducible enrichment of all metabolites of interest, and remove those 
compounds that interfere with the subsequent analytical method in order to preserve the 
integrity of the analytical system. Moreover, MS analysis can be disturbed by interfering, 
co-eluting matrix components in the samples resulting in ion suppression eff ects, especially 
when using electrospray ionization (ESI)[8]. Sample pretreatment is also required to release 
metabolites from the sample matrix and transport the analytes to a medium compatible 
with the analytical instrument. Th erefore, there is an urgent need for the development of 
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reproducible, standardized and quantitative sample pretreatment approaches for biological 
samples critical for large-scale metabolomics studies and for minimizing inter-laboratory 
inconsistencies[9].
The purpose of this review is to present the state-of-the-art sample pretreatment methodologies 
for MS-based metabolomics, not focusing on lipodomics as this is covered including sample 
pretreatment in another review article by Fiehn et al. in this issue of Trends in Analytical 
Chemistry. In addition, some of the new emerging sample pretreatment techniques, which 
have not yet been fully evaluated for metabolomics studies, will also be covered. Recent 
developments in sample pretreatment techniques such as protein removal, liquid-liquid 
extraction (LLE), solid-phase extraction (SPE) and electromigration-based extraction will be 
highlighted, and aspects such as automation and high-throughput analysis will be considered. 
Subsequently, sample pretreatment issues relevant for obtaining reliable quantitative 
metabolomics data are shortly discussed. Finally, some general conclusions and perspectives 
are given. As plants represent a particular complex case as plant cell walls are difficult to break 
and they comprise special biochemical classes, sample pretreatment procedures for plant 
metabolomics studies are not discussed in this review. 
SAMPLE PRETREATMENT FOR METABOLOMICS: CRITICAL 
ASPECTS
Sample pretreatment is an essential part of a metabolomics study as it has a major effect on 
the metabolite coverage and the quality of the results obtained. Prior to sample pretreatment, 
experimental design and pre-analytical steps such as sample collection/storage and 
stabilization need to be carefully examined and chosen in each metabolomics study (Figure 
1); however, these aspects are not covered in this review, but are discussed elsewhere [10]–
[14]. Sample pretreatment strategies used in metabolomics prior to separation and detection 
can include ultrafiltration, protein precipitation, LLE, SPE, derivatization, and evaporation 
followed by reconstitution[15]. Sample pretreatment finally results in a fraction of a sample 
that can be analyzed by a subsequent analysis platform. In this section important aspects with 
regard to the choice of a sample pretreatment technique for metabolomics are considered. 
First, the difference between targeted and untargeted metabolomics is outlined, followed by a 
discussion concerning the influence of the sample type and the subsequent analysis platform 
on the sample pretreatment strategy.
General aspects: targeted versus untargeted metabolomics
In metabolomics, two different approaches may be distinguished, i.e. the targeted and the 
untargeted detection of metabolites. The targeted approach is focused on the quantitative 
analysis of preselected metabolites in a biological sample. Targeted metabolomics approaches 
are commonly driven by a specific biochemical hypothesis, typically focusing on one or 
more related pathways of interest[16][17]. The untargeted approach involves the profiling of 
biological samples without having a priori knowledge on the nature and the identity of the 
measured metabolites. The goal is to obtain qualitative and (semi)-quantitative information, 
which can be used to compare patterns or fingerprints of metabolites that change in response 
to normal and abnormal biological processes, genetic alterations and to external stimuli, 
for example drug exposure[18]. As a consequence, untargeted metabolomics can be used 
to reveal the involvement of metabolic pathways that may not have been predicted and is 
therefore often hypothesis-generating or hypothesis-refining.
With regard to sample pretreatment, the analytical requirements for untargeted and targeted 
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metabolomics studies may be quite different. For untargeted metabolomics studies, the 
biological sample should preferably be analyzed with minimal pretreatment in order 
to prevent the potential loss of metabolites, or at least, within a certain wide biochemical 
window, metabolites should not be removed during pretreatment.  The sample pretreatment 
steps can be quite straightforward, separating low molecular weight (LMW) compounds from 
proteins and/or lipids using deproteinization and/or delipidation techniques[15]. Therefore 
in untargeted metabolomics studies of biofluids, non-selective sample pretreatment methods 
such as “dilute-and-shoot” and solvent protein precipitation are often used, since they enable 
broad metabolite coverage and high-throughput analysis[18]. Untargeted metabolomics 
approaches can also be applied to a fractionated sample obtained after e.g., a LLE and/or SPE 
step. 
In contrast to untargeted metabolomics studies, development and optimization of sample 
pretreatment procedures for targeted metabolomics are often relatively straightforward, as it 
is known a priori on which metabolite class(es) to focus. Sample pretreatment includes the 
separation of metabolites from proteins, often followed by LLE and/or off-line/online SPE for 
the selective isolation and enrichment of the target compounds, and removal of interfering 
matrix components.
Evaporation and reconstitution is often the final step during sample pretreatment in order 
to concentrate the analytes by reconstitution in a smaller volume and/or convert the solvent 
to an analysis-compatible solvent. During such a step, attention should be paid to analyte 
solubility, and potential oxidation of analytes such as thiol-containing molecules[19].
Sample type
The sample pretreatment strategy also largely depends on the nature of the sample to be 
analyzed. The protein content of biological samples is an important aspect to consider, as most 
subsequent analysis methods are not compatible with protein-rich samples such as, plasma, 
serum, cells and tissue. In contrast, urine, particularly from healthy human individuals, 
contains relatively low protein amounts, and centrifugation  followed by dilution with water 
is often all that is  required prior to analysis[18].
Metabolomics has at first mainly been applied to biofluids and cell samples, but in recent years 
also tissue samples or biopsies are becoming more studied with metabolomics[20]. For cell 
samples the quenching procedure including harvesting and washing is critical[21], however 
we do not cover that in this review. For tissue samples, sampling and homogenization without 
degradation of metabolites is critical and needs to be added to the sample pretreatment 
workflow as a first step. However, opposed to biofluids, limited research of (automated) 
sample pretreatment procedures has been performed for tissue metabolomics[15][22]. Several 
approaches for sample homogenization such as the manual disaggregation of cold tissue with 
scissors or a manual homogenizer, mechanical disruption using a bead homogenizer and a 
cryogenically cooled pestle and mortar on frozen tissue, have been used and are described 
elsewhere[23], but are beyond the scope of this review. Overall, the choice of solvent seem to 
have more influence on metabolite coverage than the sample homogenization method[24].
Dried blood spots (DBS) is a sample type which has been used for the screening of inborn 
errors of metabolism for decades now, and recently DBS samples received increased interest 
for metabolomics studies[25]. In DBS, blood or biofluid samples are collected on special 
types of absorbent paper which are then dried, and as such ready for subsequent extraction 
and analysis.  This simple and inexpensive method is easy to automate and is able to store 
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transportation at ambient conditions. Therefore, the use of DBS may have advantages for 
large-scale epidemiological studies where the pretreatment of blood and the subsequent 
storage and transport poses logistical challenges. So far only a few studies on untargeted 
metabolomics have been performed with the use of DBS. Analyte coverage for DBS seem to 
be comparable with solvent precipitation of whole blood and plasma[25]–[27].  Moreover, 
the result of stability studies seem to indicate that stability for most metabolites does not 
seem to be critical when analysis is done within a week of collection[25]. Lately, instrumental 
manufacturers have developed automated systems which can handle, extract and introduce 
the DBS extract into the analytical system, thus enabling the use of DBS for large-scale 
high-throughput profiling studies[28].However, some challenges related to DBS need to be 
examined, such as the influence of the hematocrit level and the non-uniform distribution of 
the blood spot on the sampling area[29].  
Saliva is another readily available biofluid that may contain metabolites of interest for 
diagnosis and prognosis of diseases. Nevertheless, there are only a few reports concerning 
metabolomics. The major challenge in saliva metabolomics is the relatively low abundance of 
metabolites[30]–[32]. Therefore, in this field there is a need for more sensitive analytical tools 
which may include sample pretreatment methods that allow analyte enrichment.
Subsequent analytical platform
One major aim of metabolomics is to obtain a comprehensive view of the metabolites present 
in a biological sample. As no single analytical technique covers the entire spectrum of the 
human metabolome, various complementary analytical platforms (e.g. gas chromatography-
mass spectrometry (GC-MS), liquid chromatography-MS (LC-MS), capillary electrophoresis-
MS (CE-MS) and/or direct infusion-MS (DI-MS) should be employed in order to improve 
metabolite coverage and identification power[33]–[36]. Each of these analytical platforms 
has different requirements with regard to sample pretreatment. In general, deproteinization 
is required for each analytical platform, as the presence of proteins can seriously influence 
precision, accuracy and instrument component lifetime (e.g. LC and GC columns). Moreover, 
proteins can induce severe matrix effects, may cause clogging of nanoESI emitters and can 
modify the inner surface of capillaries in CE. 
In GC-MS, sample pretreatment involves a number of steps generally including 
deproteinization, lyophilization and chemical derivatization. Chemical derivatization is often 
required to decrease the boiling point of many endogenous metabolites. There are a multitude 
of different chemical derivatization reagents used, although a two-stage process of oximation 
followed by trimethylsilylation is mostly applied[37]. However, the derivatization process may 
add more error-prone complex steps in the sample pretreatment method. Furthermore in 
general, derivatization can impose added requirements to the sample pretreatment procedure 
in order to clean up compounds that can interfere with the derivatization reactions.
In DI-MS, “dilute and shoot” after deproteinization is the most common approach, including 
optimization of the dilution factor in order to minimize ion suppression and detector 
saturation effects. Additionally, prior to DI-MS, a desalting step should be included, because 
salts can significantly contribute to ion suppression effects[38]. However, to date no general 
straightforward method is available which separates (endogenous) inorganic ions from the 
wide range of polar and often ionic metabolites.
SAMPLE PRETREATMENT TECHNIQUES
In this section recent developments in deproteinization techniques, LLE and SPE and emerging 
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electromigration-driven sample extraction will be discussed. Furthermore, throughout this 
section delipidation techniques will be discussed.
 
Protein removal
In metabolomics, the most commonly used methods for protein removal are organic solvent-
based protein precipitation (PPT) followed by centrifugation, or membrane-based techniques 
such as ultrafiltration[4]. It is preferable to use an organic solvent for PPT, since protein 
denaturation using heat or inorganic acids have been shown to result in lower metabolite 
coverage[39] and the organic solvent also disrupts binding between many metabolites and 
proteins. Actually, the latter is also true for many metabolites using inorganic acids, and some 
inorganic acids extracts metabolites more efficient than organic solvents. However, organic 
solvent PPT is able to extract both hydrophilic and hydrophobic compounds. Therefore, further 
clean-up of the extracted samples is often required as the supernatant still contains many 
components such as lipids which may disturb subsequent MS analysis (i.e. ion suppression) 
and may reduce lifetime of e.g. LC columns. As a consequence, the combination of protein 
and lipid removal is often used as an effective strategy to improve metabolite coverage and 
reproducibility. Moreover, metabolite losses may occur due to co-precipitation with proteins 
and/or poor solubility in the selected extraction solvent[40]. 
Over the past few years, the performance of various PPT procedures for metabolomics have 
been evaluated in terms of protein removal efficiency, metabolite coverage, and precision[20], 
[37], [39], [41]–[44]. The diverging practices used in these studies reveal that there is still no 
general consensus on the best PPT procedure that should be used for metabolomics. However, 
some trends are apparent: precipitation with acetonitrile or acetone seems to perform better 
in terms of protein removal, whereas PPT with methanol, ethanol or a mixture of both results 
in improved metabolic coverage and method precision. Therefore, the latter solvents are more 
often applied[28][15]. 
In conventional solvent PPT however, it is costly to include centrifugation into robotic 
automation solutions. Recent innovations have become available overcoming the need of 
centrifugation after PPT. Surface-functionalized magnetic beads have been recently suggested 
for sample pretreatment in several fields, addressing large and small molecules. König et al. 
reported a serum protein removal method based on surface-modified MagSi magnetic beads. 
Proteins were denatured using a proprietary reagent followed by the immobilization of the 
protein-adsorbing magnetic beads, by applying a magnetic field[45]. Neither centrifugation 
nor application of pressure is required, but only a time-controlled application of a magnetic 
field making this technique promising for automated high-throughput applications.
Also recently, solutions have become available for automated solvent PPT in a well-plate format 
such as the Sirocco™ (Waters), Impact™ (Phenomenex) or HyperSep™ (Thermoscientific). 
Using these PPT plates the solvent precipitated sample is filtered through a well plate by 
using a vacuum or pressure. Cao et al. demonstrated the automated removal of proteins in 
50 µL dog plasma followed by LC-MS analysis, using the Sirocco™ plate[46]. These available 
solutions could be promising for metabolomics studies, but have not been demonstrated yet. 
In section 3.3 other recently available well plates are discussed which simultaneously can 
remove proteins and lipids from a complex sample.
Other protein removing treatments have been developed that do not require a PPT or 
ultrafiltration step. Turbulent flow chromatography (TFC) is such a promising online 
technique which enables the direct injection of crude biological samples onto a column packed 





Recent developments in sample pretreatment techniques for mass spectrometry-based metabolomics |           19
using stationary phase functionality. After the sample is injected into a turbo flow column 
the high flow-rate of 1.5-5.0 mL/min generates turbulent flow conditions inside the column. 
Small analyte molecules are retained via diffusion into the pores, while proteins are washed 
to waste. In 2010, Michopoulos et al. demonstrated the use of TFC for the protein removal in 
a metabolomics study of plasma, followed by LC-MS analysis. A comparison between TFC 
and methanol-based PPT was made and resulted in similar numbers of molecular features 
(2900), with a somewhat poorer repeatability for TFC. TFC reduced the concentration of 
phospholipids 10-60 fold, probably because the protein binding compounds (such as certain 
lipids) were washed away[47]. The principle of TFC has shown potential for the direct analysis 
of crude serum samples in automated, high-throughput metabolomics studies, however at the 
price of very high flow-rates and substantial consumption of solvents.
Liquid-Liquid-Extraction
LLE enables the extraction of metabolites into two fractions (aqueous and organic phase) 
that separately contain polar and apolar compounds and which can be then independently 
analyzed. In LLE it is challenging to extract polar analytes into an organic phase, therefore in 
metabolomics LLE is mostly used for sample cleanup purposes, predominantly for the removal 
of lipids. According to Folch et al.[48] and Bligh and Dyer[49], chloroform extraction can be 
used to recover all major lipid classes, but the use of dichloromethane has been suggested as a 
less toxic alternative[50]. Recently Matyash et al. reported that substituting chloroform with 
methyl tert-butyl ether (MTBE) also recovered the major lipid classes with the same or better 
recovery, but with reduced health risks[51]. Moreover, MTBE has a more advantageous phase 
configuration in which the MTBE phase is at the top and where the precipitated proteins 
are at the bottom (instead of between the phases using chloroform-based LLE), therefore 
simplifying online coupling. For these reasons, in the last years several papers have been 
published comprising LLE with MTBE for metabolomics studies. Chen et al. presented an 
untargeted approach to simultaneously perform metabolomics as well as lipidomics from a 
small piece of tissue sample (10 mg) based on a MTBE LLE. After the MTBE-based extraction, 
a mix of the resulting polar and apolar fraction was pooled, evaporated and reconstituted and 
analyzed with ultra performance (UP)LC-MS. This approach was comparable or superior 
in yield (3429 vs. 2641 features) and reproducibility (0.3-9.9% vs. 0.5-15.4%) to a standard 
methanol extraction for the profiling of polar and apolar metabolites[52].
Recently the group of Barbas and co-workers developed a MTBE-based extraction method 
by performing the whole sample preparation and analysis within and from a single LC-
vial, which they coined as in vial dual extraction (IVDE)[53]. The upper MTBE and lower 
methanol-water phases were successively injected onto an reversed-phase (RP)LC-MS system 
directly from the vial by the adjustment of the instrument needle height in two separate runs. 
This way, pretreatment time and analytical variation was reduced. To date, this approach was 
tested for the direct LC-MS analysis of 20 µL plasma resulting in over 4500 reproducible 
features, as well as DBS samples for untargeted metabolomics[54], see Figure 2, and also for 
the application of a biological case [55].
In 2012 Saric et al. optimized a single LLE by varying solvent mixtures for comprehensive 
untargeted metabolic profiling of the aqueous phase from the Fasciola hepatica using 
a multiplatform approach comprised of RPLC-MS, Hydrophilic Interaction Liquid 
Chromatography (HILIC)-MS and CE-MS. A choloroform:methanol:water mixture with 
proportion of 15:59:26 (v:v) delivered the best compromise for all five analytical methods 
in terms of the number of extracted metabolites and resulted in 142 uniquely identified 
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Figure 2: Schematic illustration of the IVDE method comprising the (from bottom to top) precipitated proteins, 
aqueous and organic MTBE layer. Both organic and aqueous layer are injected on a LC separately for apolar and polar 
metabolite analysis respectively. Figure adapted with permission from [55].
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metabolites, see Figure 3[56].
LLE can also be used for cleaning up samples in order to obtain effi  cient labeling in 
metabolomics. Recently, Peng et al. reported an improved method for detecting organic acids 
based on LLE followed by diff erential isotope p-dimethylaminophenacyl (DmPA) labeling of 
the acidic metabolites[57]. It is shown that this strategy off ers superior performance (3-fold 
increase in putative detected metabolites) over the method of direct labeling of metabolites in 
biofl uids such as human urine.
Still, conventional LLE as described above has drawbacks being time-consuming and diffi  cult 
to automate (e.g. in a multi-well format), due to the necessary mixing and oft en required 
centrifugation steps. 
New LLE approaches have emerged in overcoming automation diffi  culties, as discussed 
below. Additionally, these approaches may use less organic solvent than conventional LLE.
Supported Liquid Extraction (SLE), or solid-supported liquid extraction, is an emerging LLE-
based technique for metabolite analysis in which an aqueous sample phase is absorbed into a 
chemically inert, porous, high-surface area diatomaceous earth support. Th e organic phase is 
passed through the cartridge and a highly effi  cient extraction is obtained, therefore bypassing 
cumbersome mixing and centrifugation steps (Figure 4). As a consequence, the SLE is easier 
to automate and uses less organic solvent than conventional LLE[58]. Several commercial 96-
well plate SLE are available, compatible with automated high-throughput analysis. Although, 
to date, the analysis of drugs in biofl uids is one of the most popular application of SLE, it may 
also be promising for high-throughput sample clean-up in metabolomics[59][60]. 
Figure 4: Schematic picture of a typical SLE procedure, modifi ed from[84].
Miniaturization of LLE is another trend such as liquid-phase microextraction (LPME) tech-
niques [61]. In LPME, extraction generally takes place from an aqueous sample phase into a 
small amount of a water-immiscible organic acceptor phase, and reducing the acceptor-to-
donor ratio. Even though this miniaturized approach might be promising in metabolomics 
studies where limited sample amounts are available, no recent metabolomics applications of 
LPME techniques have been reported so far. 
Another development in LLE is the integration of ultra-sound in sample pretreatment. Th e 
application of ultra-sound in LLE can signifi cantly shorten the time required for extraction 
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of metabolites which increases sample throughput. So far, the potential of this approach has 
been only demonstrated for a few metabolomics studies [62].
Solid Phase Extraction
SPE is an eff ective sample pretreatment method for the removal of interfering substances and 
for the enrichment of analytes. A variety of extraction sorbents is available for SPE; examples 
are: reversed-phase materials including phenyl groups or polymeric material, weak and strong 
ion exchange materials including amino groups, mixed mode materials covering for example 
reversed- phase and weak ion exchange and stationary phases for HILIC separations. Th e-
refore, SPE can address more specifi c molecular characteristics of target analytes and allows 
the design of protocols which can be more selective than LLE[5]. However, due to sorbent 
selectivity, obtaining high metabolite coverage may be challenging, especially in untargeted 
metabolomics. Th erefore, within targeted metabolomics, the combination of SPE and LC sy-
stems using reversed-phase sorbents are most oft en employed for clean-up (desalting and de-
lipidation) and enrichment of relatively hydrophobic analytes. Th is approach can also be used 
for analysis of more polar compounds if employing alternative phases (e.g. C30) or ion-pairing 
reagents[63]. However complementary principles may be more appropriate, such as mixed-
mode or HILIC phases. RP SPE-and LC columns are used in most online SPE-LC systems and 
are now widely commercially available in various dimensions[64].
Recently, Yang et al. reported a combined untargeted MTBE-based LLE and SPE (NH2) me-
thod to improve the coverage of the metabolome in plasma caused by eff ective delipidation.
[65]. Th ey separated the sample into fi ve fractions including aqueous species, lipids, fatty 
acids, neutral lipids and hydrophobic lipids prior to RPLC-MS and HILIC-MS analysis, and 
detected over 3806 versus 1851 molecular features using methanol extraction only (Figure 
5).  Improved reproducibility was shown with CV’s below 15% for the combined LLE-SPE 
method, compared to 30% using the methanol method. However, this LLE-SPE method is 
time-consuming and therefore may be less suitable for high-throughput applications. 
Figure 5: Venn diagrams showing the comparison of MTBE extraction vs MTBE-SPE fractionation method. Ex-
traction was performed and resulting samples were analyzed using positive mode LC-MS by using RPLC (lipids) or 
HILIC (aqueous). (A) Comparison of lipid fraction, fractionated lipid fractions and pellet fraction; (B) comparison 
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Fully automated SPE has clear advantages over conventional LLE and can outperform manual 
protocols in terms of reproducibility and sample throughput. Off-line automated SPE sam-
ple pretreatment using robotics is available, as well as SPE platforms coupled on-line to MS 
such as the Agilent Rapidfire system which is a robotic high-throughput SPE-MS system or 
the Spark Symbiosis™ system which combines SPE and LC in parallel for high sample throu-
ghput. These systems could be suitable for rapidly tailoring an efficient targeted metabolite 
extraction protocol, by employing the various SPE materials that are currently available and 
optimizing organic solvents, pH or ion strength.
As discussed, delipidation of the sample has gained increased interest, since it can reduce ion 
suppression effects and can increase column lifetime. Recently, several commercial available 
lipid depletion plates have become available such as the Hybrid SPE™ (Sigma Aldrich), Ostro™ 
(Waters), Captiva™ ND (Agilent) and the Phree™ (Phenomenex) 96 well plates which can re-
move lipids as well as proteins from a sample in a single step. These recent innovations are ef-
fective for removing phospholipids and compatible with automation and high sample throu-
ghput, but their protocols dilute samples and do not easily allow sample concentration[66]. 
In SPE recent promising innovations regarding miniaturization, sorbent material and sorbent 
functionality has appeared in literature and is discussed below.
Also in SPE there is a trend towards miniaturization. One such approach is solid-phase mi-
croextraction (SPME) in which a fiber is coated with a thin layer of sorbent material. SPME 
can integrate sampling, extraction, concentration and sample introduction into a single 
step[61]. For more details the reader is referred to the review article by Pawliszyn et al. in this 
issue of Trends in Analytical Chemistry. Microextraction by packed sorbent (MEPS) is a more 
recent miniaturized SPE approach that integrates the sorbent cartridge in a microliter syringe 
which can be used in e.g. an autosampler. Sample and solvent volume has been scaled down 
to the microliter level and is therefore very compatible with volume-limited samples. Several 
MEPS sorbents are available, including reversed- and normal phase, HILIC, mixed mode and 
ion exchange functionalities[67]. This technique could be very promising in online automa-
ted, high-throughput metabolomics studies.
The use of alternative SPE sorbent chemistry based on aptamers could also bring potential 
to highly selective targeted metabolomics approaches, for example by employing RNA oli-
gomers that have high affinity to small molecule targets including ATP and several amino 
acids[68]. Another interesting alternative sorbent is the use of immobilized ionic liquids in 
sample pretreatment for the extraction of polar compounds[69]. However, the potential of 
these alternative sorbents for metabolomics has not been demonstrated yet.
The use of monolithic material in SPE columns has gained increased interest. This material 
has several advantages over the use of particle sorbents including low back pressure, high 
efficiency and a low dead volume[70]. Recently, Abe et al. used a spin column, which was pac-
ked with a monolithic silica disk, for the extraction of drugs from human urine. In this spin 
column, the monolithic silica works as a frit, the surface to volume ratio is larger than the use 
of silica particles and it requires a small volume of extraction solvent [71]. As a consequence 
this material could be promising for metabolomics, but this has not been demonstrated yet. 
However, sample loading, washing and elution were accomplished by centrifugation of the 
spin column, which makes it less suitable for robotic automation.
Carbon nanotubes (CNT) is another SPE sorbent material which also demonstrated to have 
great potential. CNT are characterized by highly specific surface area, high mechanical streng-
th, chemical stability and strong adsorbance capacity. By modifying the surface of CNT using 
carboxyl groups, the extraction of highly polar analytes is enabled[72]. As a consequence 
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CNT could be promising for metabolomics, however it has not been demonstrated yet.
Electromigration-based Extraction Techniques
Electromigration-based extraction utilizes an electric field to induce selective migration of 
charged compounds. A major part of the metabolome can be targeted with this approach, as 
many metabolites are charged in solution or can be made charged by adjusting the pH. Elec-
tromigration-based sample extraction has received increased attention in the past 5 years[73]
[74]. In this section, we outline recent developments in two techniques that may be promising 
for metabolite analysis: electromembrane extraction (EME) and electroextraction (EE). EME 
is based on an the application of an electric field between a donor phase and an acceptor phase 
which are separated by a membrane filled with an organic solvent in its pores[75]. Via the 
membrane, which consists of a polymeric material, analytes are extracted from a sample to an 
acceptor compartment. The electric field enhances the extraction rate of the analytes and as 
a consequence it is fast and typically enriches analytes (expressed in concentration units) by 
one order of magnitude. Strieglerová et al. demonstrated the potential of EME for the targe-
ted extraction of endogenous amino acids from human plasma and urine[76]. Here, a simple 
EME device was coupled with capillary electrophoresis with capacitively coupled contactless 
conductivity detection. In total, 12 endogenous physiological amino acids were analyzed in 
human plasma, whole blood, serum and urine with peak area RSDs ranging from 1 to 13%. 
However, not all endogenous 20 physiological amino acids were recovered[76]. Further op-
timization of the composition of the liquid phase of the membrane may result in an EME 
protocol that is capable of extracting a wider physicochemical range of analytes in one run.
EE is an electromigration-based sample enrichment technique in which analytes are concen-
trated from a large donor phase, through one or more liquid-liquid interfaces, into a small 
acceptor phase[77]. In the most simple set-up, the donor phase is an organic solvent, which 
may contain some water to dissolve ions as has been done for ethyl acetate, and the adjacent 
acceptor phase is an aqueous phase; both phases should be immiscible. It has been shown 
that EE allows the fast enrichment of metabolites and is promising for high-throughput ap-
plications and analysis of low-abundant metabolites [78][79]. The driving force of EE is an 
electric field that is applied over the liquid-liquid system: in the donor phase a very high field 
strength is present. When the metabolites enter the aqueous acceptor phase, they enter a very 
low electric field, their migration speed diminishes and they are enriched in a small volume. 
In 2012, Lindenburg et al. presented EE of acylcarnitines from human urine. EE took place 
in a wide-bore PTFE capillary, was coupled online with LC-MS via a switching valve and was 
automated. Within a few minutes, acylcarnitines at the nM level in urine were enriched up to 
1000 times with excellent repeatability (below 12%) in comparison with conventional LC-MS 
injection, see Figure 6 [78]. 
Recently, Raterink et al. developed a new EE strategy consisting of three liquid phases, so-cal-
led 3-phase EE. The extraction in 3-phase EE takes place from the aqueous donor phase, via 
an organic phase that acts as a filter, into a hanging acceptor droplet. The selectivity of 3-phase 
EE can be altered by changing the composition of the organic filter phase. After the 3-phase 
EE procedure was completed, the acceptor droplet was transferred to nanoESI-DI-MS. The 
3-phase EE–nanoESI-DI-MS was successfully applied to the targeted analysis of acylcarni-
tines spiked to human plasma with a good linear response over 2 orders of magnitude and 
repeatability better than 15%, and could be fully automated. Importantly, it was demonstrated 
that proteins were excluded from extraction, indicating that 3-phase EE can cope with dif-
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Until now, it has been shown that electromigration-driven sample extraction methods are in 
principle promising for metabolomics. Its approach can off er speed, selectivity and excellent 
potential for both miniaturization and high-throughput analysis. Th erefore, we expect that 
electromigration-based sample extraction will be used as complementary tools for metabolo-
mics studies in the upcoming years. However, an important aspect to study is the applicability 
of these methods to a wider range of metabolites.
QUANTITATION AND VALIDATION
Th e systematic evaluation and validation of an extraction procedure for a given biological 
sample matrix is necessary in order to obtain reliable and meaningful metabolomics data. In 
this section, attention is paid to some issues that should be considered during sample extrac-
tion to obtain reliable quantitative metabolite data.
Th e performance (i.e. recovery, repeatability, enrichment factors etc.) of the extraction me-
thod should be critically examined by using proper internal standards. In untargeted metabo-
lomics, the performance of an extraction method is still oft en only evaluated in terms of the 
number of molecular features observed[15]. Th is strategy may provide useful information, 
however specifi c information concerning metabolite enrichment and recovery, or metabolite 
losses due to e.g. protein binding, is not provided. In this context, we suggest using multiple 
stable isotopically labeled internal standards, each representing a metabolite (sub)class, du-
ring sample extraction in order to evaluate the performance of the method[80][81]. Recently 
Strassburg et al. developed a quantitative (precision RSD ranged from 4% - 15%) and sensitive 
(down to nM levels) LC-MS/MS method for the profi ling of approximately 100 oxylipins in 
human plasma by using 11 deuterated internal standards which were considered represen-
tative for the diff erent compound classes[82]. Method validation in untargeted metabolo-
mics is more challenging than in targeted metabolomics regarding the choice of the internal 
standard. Another elegant approach to tackle these challenges is the use of 13C-labeled cell 
extracts, which has been recently used for the quantifi cation of 91 metabolites representing 
central carbon and energy metabolism[33]. For targeted metabolites, isotopically-labelled 
Figure 6: Comparison of (A) LC-MS obtained for a 0.1 µL injection of urine and (B) cEE-LC-MS of 100 µL urine; 
urine was spiked with acylcarnitines. Figure reprinted with permission from[78].
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metabolites can be used to correct for potential matrix effects (ion suppression/enhancement) 
and batch-to-batch effects of the corresponding endogenous metabolites. 
At present, there is no consensus yet on the most suited type of sample extraction method that 
should be used for a certain biological sample matrix or question. Standardization and inter-
laboratory comparisons are crucial in order to demonstrate the validity of a sample extraction 
procedure for metabolic profiling of a particular biological sample, and this would help to 
compare different metabolomics studies published or even accessible in data repositories. For 
inter-laboratory comparisons, reference material[83] should be used and preferably absolute 
concentrations should be provided for metabolites. Especially when reporting relative con-
centrations, as is often the case in untargeted metabolomics studies, it is crucial to use pooled 
samples and/or internal standards as quality controls and for correction of variations and 
possible biases in the overall analytical procedure during studies[81].
CONCLUSIONS AND OUTLOOK
Sample pretreatment is a key step in the metabolomics workflow as it has a major influence on 
the overall quality of the obtained metabolic profile, metabolite coverage and sample through-
put. This review highlights that the development of sample pretreatment for metabolomics is 
still an active area of research. Although no universal sample pretreatment technique is avai-
lable for the comprehensive analysis of all metabolites in a given biological sample, the combi-
nation of protein and lipid removal is often used as an effective strategy to improve metabolite 
coverage and reproducibility. In LLE several developments are made towards the compati-
bility with automation, of which supported liquid extraction is one of the most promising 
techniques, readily available in a well-plate format. As a consequence, deproteinization and 
delipidation can be performed by using LLE as well as SPE techniques in a fully automated, 
high-throughput manner. The recent innovations in automated offline well-plate extraction 
(including protein precipitation, LLE and SPE) or online extraction (including turbulent flow 
chromatography) have allowed fast sample cleanup and partly removed the bottlenecks asso-
ciated with sample pretreatment. All these techniques are very promising for metabolomics, 
however the effective extraction of polar metabolites is still challenging and the separation of 
polar analytes from interfering salts is a hurdle for some analytical methods which still needs 
to be overcome. New emerging electromigration-based sample pretreatment techniques are 
promising and their compatibility with automation has been demonstrated. Still, more re-
search is needed in order to exploit the full potential of these techniques for metabolomics.
To improve quantitative aspects during sample pretreatment, more research is needed in the 
use of internal standards, such as 13C-labeled cell extracts. Proper internal standards are cru-
cial to correct for matrix and batch effects and to obtain insights in metabolite enrichment 
and recovery. In the future, sample pretreatment procedures should not only be automated 
and fast, but also quantitative and standardized so that metabolomics data of different studies 
are comparable within and between labs, which would be needed for breakthroughs in bio-
medical and pharmacological research.
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Chapter 3
Rapid metabolic screening of early 
zebrafi sh embryogenesis based on 
direct-infusion-nanoESI-FTMS
ABSTRACT
Single zebrafi sh eggs were rapidly profi led using high resolution nanoelectrospray direct infu-
sion mass spectrometry with limited sample preparation and without separation. The analysis 
time per sample is around 1 minute. Using this approach the different developmental stages 
of zebrafi sh eggs can be characterized by their active metabolites. Five different development 
stages with distinct metabolic fi ngerprints could clearly be observed when untargeted analysis 
is performed and the data are plotted using principal component analysis (PCA). Using this 
approach early embryogenesis is followed with a time resolution of 1 hour and 102 features 
proved relevant. Of these, signifi cant number of putatively identifi ed compounds has not been 
reported earlier to have any association with early zebrafi sh embryogenesis yet. The onset of 
gene expression and the increase in energy requirement is refl ected by the measured metabo-
lome complementing earlier reported transcriptomics studies from a systems biology point of 
view. By deyolking and dechorionation eggs at two early developmental stages, we were able 
to observe distinct changes in localized metabolism. 
Chapter 3
34         | Chapter 3
INTRODUCTION
In the past decade the Zebrafish (Danio Rerio) has become a popular vertebrate model system 
for studying human development and disease[1]–[3]. This is because the development of the 
zebrafish is very similar to the embryogenesis in higher vertebrates, including humans. But 
unlike mammals, zebrafish develop from a fertilized egg to an adult outside the female in a 
transparent egg. This makes it possible to observe developing embryos from the single cell to 
the entire organism level[4]. The development time of the embryo is fast (after about 2 days 
most common vertebrate specific body features can be seen including brain, eyes, ears and all 
internal organs) and the number of offspring is large (100-200 eggs per mating). Moreover, 
because they are small, available in large numbers and maintained at low cost, zebrafish em-
bryos are ideal as model systems in high-throughput whole organism preclinical drug scree-
ning and toxicology studies as less drug is required, a larger number of animals can be used 
and less ethical issues are associated[5], [6]. Therefore, the zebrafish embryo can bridge the 
gap between cell assays and rodent assays.
The external and rapid development as well as transparency of zebrafish embryos is ideal for 
observable phenotype-based screening at cellular and organ-tissue level using live imaging, 
for example using a complex object parametric analyzer (COPAS)[7]. Although these pheno-
typic changes are adequate for specific drug-induced biological responses, they don’t reveal 
system-wide responses and are not sufficient in elucidating the mode of action or potential 
toxicity of drugs[6]. With the ever increasing interest in studying biological systems in a ho-
listic manner (systems biology) the necessity for delivering qualitative and quantitative data 
of complete biological systems for which zebrafish offer many advantages becomes clear[8]. 
Metabolomics is a powerful tool within systems biology and investigates the complex inter-
actions of the metabolism and metabolic networks[9]–[11]. One of the greatest strengths of 
metabolomics is the ability to capture a molecular snapshot of metabolites as reactants, inter-
mediates or products of (enzyme-mediated) biochemical reactions. Metabolomics comple-
ments genomics, transcriptomics and proteomics for metabolites are in a unique position as 
they are building blocks for all other biochemical structures including proteins (amino acids), 
genes and transcripts (nucleotides) and cell walls (lipids) [12], [13]. 
So far, the number of metabolomics studies on zebrafish embryos is limited[14]–[18].  Most 
of these studies included chromatography which is time consuming and therefore less sui-
table for high-throughput metabolic screening. Recent studies outlined the power of high-
resolution direct infusion mass spectrometry (HR-DI-MS) metabolomics on other complex 
samples[19]–[22]. Most of these studies were performed using flow injection electrospray 
ionization (ESI)-MS and therefore did not explore the advantages of nanoESI over normal ESI 
with respect to ionization efficiency and ion suppression effects[23].
In this paper we describe a rapid metabolic profiling method of zebrafish eggs, based on lysis 
of single zebrafish eggs and subsequent HR-nanoESI-DI-MS analysis. A clear metabolic dis-
tinction between developmental stages in early embryogenesis is described and up-and down 
regulation of some important primary metabolites is shown. By deyolking and dechoriona-
ting the embryos, we were able to highlight localized and time resolved metabolism.
MATERIALS AND METHODS
Chemicals and materials
Methanol was from Biosolve (Valkenswaard, The Netherlands). Water was obtained from a 
Millipore high purity water dispenser (Billerica, MA, USA). All solvents were HPLC grade. 
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were bought from Cambridge Isotope Laboratories (Andover, MA, USA) and added to the 
samples at a concentration of 1 µg/mL. Reserpine (also used as internal standard) was supp-
lied by Fluka (Buchs, Switzerland) and added to the samples at a concentration of 500 ng/mL.
Whole embryo experiments
Two wild type (strain A/B) parent groups were maintained under standard zebrafish aqua-
rium conditions. Since many cell differentiation and phenotopic processes occur within 48 
hours after fertilization, the following 5 early developmental stages were chosen: the 4-cell (1 
hpf), 64-cell (2 hpf), 1k (3 hpf), 50% Epiboly (5 hpf) and the 18-somites stage (18 hpf) For 
each of the five developmental stages 8 eggs were analyzed separately in triplicate.
 
Lysation protocol for the whole embryo
1) The egg was optically selected under a microscope in the relevant developmental stage and 
pipetted to a 1.5 mL eppendorf tube. As much as possible of the egg water was removed.
2) The egg was washed 3 times with 1 mL demineralized H2O.
3) 100 µL (9:1, v/v methanol:water) including the internal standards (1µg/mL labeled amino 
acids+ 500 ng/mL reserpine) was added. Immediately the sample was snap-frozen in liquid 
nitrogen for 2 minutes. This step should quench metabolism and precipitate the proteins.
4) After snap-freezing the sample was sonicated for 2 minutes to lyse and to homogenize the 
sample and visually inspected to confirm homogeneity. In case of non-homogeneity the sam-
ple was snap-frozen and sonicated a second time.
5.)Precipitated proteins were spun down by centrifuging the lysate at 16.1 krcf at 0 °C. The 
supernatant (80 µL) was used for DI-MS analysis.
Deyolking and dechorionating experiments
Two developmental stages 1kcell (3 hpf) and somite (18 hpf)) of the same wild type were 
measured (pool of n=10) in triplicate.
Dechorionating
1) The chorion of the egg was removed mechanically by a tweezer and was put in a 1.5 mL ep-
pendorf tube. Using this methodology only the membrane of the chorion could be analysed. 
The same lysation protocol as described above was used however, instead of 100 µL , now 1 
mL of solvent + IS (since it was a pool of 10 egg instead of a single egg) was added and no 
washing was done (since it would remove parts of the sample). 
Deyolking
1) After dechorionating the egg only consists of the yolk with its cells (see Figure 1). The yolk 
was removed by adding a Ringer solution to the egg and pipetting it up-and down a few times. 
2) Subsequently, the sample was centrifuged for 5 minutes at 0.8 krcf (to segregate the cells) 
and the supernatant (including the yolk) was pipetted away. This way only the cells of the 
embryo could be analyzed[4].
3) 1 mL of IS was added to the pallet and the same lysation protocol was used as described 
above.
Non-fertilized egg (pool of n=10, in triplicate)
1) First the non-fertilized egg (only 3 hpf stage) was dechorionated resulting in only the yolk 
with its fluid. This way also the fluid in the yolk could be analyzed.
2) 1 mL of IS was added and the same lysation protocol was used as described above.
In the deyolking experiments again also whole-eggs were included as a reference.
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MS Analysis
Th e analyses were performed by DI-nanoESI-MS in the positive ion mode using the automa-
ted Advion NanoMate Triversa system (type ‘A’ chip) coupled to a LTQ-FT Ultra (Th ermo 
Fisher Scientifi c). Eppendorf 96 well plates were used on which all the samples were randomly 
distributed. Of each sample 5µL was infused using a pressure of 0.2 psi and an electrospray 
voltage of 1.48 kV in the positive ion mode. Mass spectra were recorded using three scan 
ranges containing 20 scans: 50-250; 250-500; 500-1000 m/z (in this order) at a resolution of 
100.000. Separate scan ranges instead of one full scan range was chosen in order to enhance 
sensitivity. Th e MS was tuned with inlet capillary temperature of 120 °C, capillary voltage of 
35V and the tube lens voltage of 50 V. For tandem MS as well as for the deyolking experiments 
an LTQ-Orbitrap XL (Th ermo Fisher Scientifi c) was used with inlet capillary temperature of 
120 °C, capillary voltage of 25 V and the tube lens voltage of 80 V.
Data processing 
Th e fi rst 10 scans (approximately 10 seconds) of every sample were averaged using XCali-
bur soft ware (version 2.0.7; Th ermo Fischer). Th ese average scans were stored in separate 
fi les. In some samples no spray or no stable spray was obtained, i.e. no average scan could be 
made. Th ese samples were discarded from further processing. Using a resolution of 100.000 
(at 400 m/z) each sample typically resulted in 5 to 10 thousand unique features in the average 
spectrum. In contrast to hyphenated MS data, the drawback of DI-MS data is that all masses 
co-elute. Aligning features over samples now is solely based on accurate mass. To align the 
masses across the diff erent samples we created mass-bins of very small sizes (0.0003 Da) and 
assigned the diff erent masses to the nearest bin. For a mass range of 50 to 250 m/z this genera-
ted approximately 650.000 mass bins. All data analysis was done using Matlab (version 2011a 
64bit; MathWorks). In order for the data to be analyzed in Matlab the Xcalibur averaged spec-
tra fi les were converted to mzXML format (ReAdW version 4.3.1).
RESULTS AND DISCUSSION
Our primary goal was to explore the possibility of discerning developmental stages in zebra-
fi sh embryogenesis by applying HR-nanoESI-DI-MS analysis on lysed eggs. Th erefore, re-
producible and high-quality MS data should be generated and preferably an automated data 
processing tool is required. Th e implementation of these (automated) tools, viz., acquisition 
and processing strategy, forms an integral part of the proposed method. Aft er binning, empty 
and almost empty features were removed. Th is reduced the number of features from ~650.000 
to ~30.000. To reduce analytical variation as much as possible, the data was normalized by se-
lecting the optimal internal standard for each compound from the mix of internal standards. 
Th is selection was based on the minimization of the RSD of the response of replicate measure-
Figure 1: Photomicrograph of zebrafi sh embryos: (left ) 1k-cell stage and (right) somite stage. In both stages some of 
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ments[24]. Beckmann et al. [21] normalized the data by using the total ion current, however 
with our data this would reduce group diff erences which is not desirable. To enable statistical 
interpretation, features that showed consistency per group were selected [25]. Features were 
considered consistent if they were either present or absent in all samples for a group. However, 
as we were interested in changes between developmental stages, we allowed for, at most, one 
missing feature in the replicates of a particular developmental stage. Th is step further reduced 
the number of possible features to ~5.000. As we anticipate diff erences between the samples 
to be apparent in the most abundant metabolites for that sample, we focused on the top 100 
features per sample reducing the number of features of interest to 200. Out of these 200 fea-
tures, 102 showed signifi cant diff erences in concentration between the diff erent developmen-
tal stages. As observed in other complex samples in other research[20], the lowest mass range 
(50-250 m/z) showed a clear clustering of the diff erent developmental stages (see Figure 3). 
Th is would indicate that at least small molecules relate to metabolic variations between the 
ages of the embryo.
Robustness/validation of the analytical method
Metabolomics oft en deals with diff erential analysis of fi ngerprints[20] to highlight biomar-
kers. Especially, when a large number of analytes is taken into consideration absolute quanti-
tation is only reported in some cases. In order to be able to give some indication of the analy-
tical rigor of the method, the RSD of repeated measurements, for example using QC samples 
is oft en reported. In the absence of QC samples , the RSD was calculated for each feature using 
a RSD approach based on multiple sets of replicated measurements[26] and classifi ed in one 
of the six possible classes (0-0.1,0.1-0.25,0.25-0.35,0.35-0.5,0.5-1 and >1). Th e result of this 
inter-assay reproducibility for the 102 features is displayed in Figure 2. As can be seen almost 
half of these features showed an RSD lower than 25%.
Figure 2: Histograms showing the technical reproducibility of the measurements. 45% of the 102 features has an 
RSD <25%.
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One could argue that by focusing on the top N features too much information is being dis-
carded. For example, tryptophan, hypoxanthine, carnosine, methionine, aspartic acid, pro-
pionylcarnitine, dimethyllysine, methyllysine, acetyllysine and serine were discarded (see 
Supporting Figure 1). However, including lesser abundant features invariably led to higher 
RSD values for these new features. This could be explained by ion suppression effects: as we 
measured crude, complex samples containing various compound classes and compound sizes 
as a result of lysis of the whole embryo. As a comparison: yeast has an estimated 1100 me-
tabolites which is expected to be significantly less than the metabolome of a whole zebrafish 
embryo[13]. This together with using nanoESI lead to quite some sample-loss due to, e.g., 
clogging of the nanoESI emitter, which resulted in a loss of replicates. Nevertheless, by discar-
ding the missing variables from the dataset, still 102 features were extracted which revealed 
the developmental stage differences (Figure 3). (FDA suggests that for LC-MS profiling an 
RSD of 20% is acceptable[13]).
 
Identification of metabolites
Out of the significant 102 features 27 separate metabolites (36 features; including all adducts) 
were putatively identified (see Table 1). Identification was based on (1) search of HR-MS 
data against HMDB (Human Metabolome project Data Base) and (2) searching MS/MS data 
against HMDB comparison to standards. After the first HMDB search 171 possible structures 
were found of which 21 were unique and 150 isomers. From those 150 remaining isomers, 6 
were identified using tandem MS and subsequent database search or comparison to standards.
Table 1: RSD values of the 27 (putatively) identified features. The features that were not found in the cited references 
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Figure 3: PCA score plots indicating a visible diff erence between 5 diff erent developmental stages. For these plots 
only one PCA model was created using all samples and only those features with an RSD < 30%. Th e blocks represent 
the 18 hpf stage, the diamonds the 5 hpf stage. Th e circles represent the 1, 2 and 3 hpf respectively.
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Table 1 shows all the putatively identified features, with their associated RSD values. Remar-
kably, the potassium adducts nearly always shows the best RSD, followed by the sodium ad-
ducts and finally the protonated molecule.  As our samples were not acidified, alkali adducts 
were not suppressed. The reason for the pre-dominant potassium adducts is most likely due to 
relative high potassium concentration inside the cell as opposed to the relative high concen-
tration of sodium outside living cells. From several of the 27 (putatively) identified features 
the boxplots with their up-or down regulation are shown in Figure 4. Still 63% of the 102 
significant features remained unidentified. This confirms that further research is required to 
expand the zebrafish metabolome database in order to increase identification using DI-MS 
methods[16].
Biological relevance
In order to evaluate the possibility of using this technology for early fingerprinting of zebra-
fish embryos, different stages after fertilization were analyzed using this approach. 1, 2, 3, 5 
and 18 hours post fertilization (hpf) were tested. The PCA in Figure 3 shows the somite stage 
(18 hpf) as the most distinctive group as well as having the most within-group variation. The 
fact that this stage is most distinctive from the other groups can be explained by the fact that 
different tissue types and organs (i.e. nervous system, skin, blood, and heart) begin to form 
at this stage. Since small time differences result already in differences of organ formation this 
will lead to biological variations in the different samples, explaining why this time point has 
the most variation in the metabolome measurements. Thus, as Chen et al. [16] remarked, the 
differences in the metabolome between the early embryonic stages may reflect the embryo-
logical properties of the cells. These results show that the zebrafish embryonic metabolome 
reflects differentiation. With our method we were able to observe a post fertilization time-
trend with a time resolution of 1 hpf. The metabolic shift between 1, 2, 3 and 5 hpf can be 
clearly observed indicating that in early embryogenesis the metabolome changes quickly and 
significantly. As can be seen, the metabolome of the first three stages (1, 2 and 3 hpf) closely 
resemble each other. This suggests that zygotic gene transcription only begins at the onset of 
the midblastula transition (3 hpf)[27]. 
The boxplots in Figure 4 allows us to go more into depth regarding the biology during early 
embryogenesis. Interestingly, the increase in concentration of dimethylarginine can be a re-
sult of the enhanced methylation and acetylation metabolism of lysine and arginine which 
play an important role in histone activity and gene expression[28][29]. When we searched for 
other methylated and acetylated forms of lysine and arginine by discarding the described mis-
sings data cleaning step (resulting in a larger data subset) we also found increasing trends for 
dimethyllysine, methyllysine and acetyllysine (Supporting Figure 1). Although we are aware 
these analytes did not make it to the best 102 features, these findings correlate to the onset of 
gene expression at 3 hpf.
The increased concentration of spermine dialdehyde could reflect the turnover of the po-
lyamine spermine which plays a role in normal and neoplastic growth as well as the (uni)
directional transport of molecules by GAP junctions which is an important process in early 
embryogenesis[30][31].
It can also be observed that the concentrations of several amino acids and biogenic amines 
are increasing during early embryogenesis. Apparently the embryos are able to release amino 
acids from storage proteins to provide the cells with building blocks and energy already in an 
early stage. Some of these reveal more than a 10-fold change going from 1 hpf to 18 hpf. In the 
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Figure 4: Boxplots of the up-and down regulation of some of the (putatively) identified metabolites through the five 
different developmental stages (for arg, his, actylcarnitine, lys, dimethylarg and spermine dialdehyde the (M+H)+ plot 
is shown, for tyr, glu, creatine,phe, pro, leu, val, ala, homoserine, asparagine, phophoethanolamine, acetylasparctic 
acid the (M+K)+ plot is shown, and for isovaleraldehyde the (M+NH4)+ plot is shown. The y-axis represents the ratio 
of the analyte/optimal internal standard.
increase in energy requirement for evoked muscle contraction starting at around 18 hpf[32]. 
Isovaleraldehyde, vinylacetylglycine could reflect the degradation of branched chain amino 
acids like valine and (iso)leucine, both associated with the increase in energy requirement. 
The concentration of hypoxanthine (see supplemental figure) is decreasing which can be ex-
plained by the enhanced DNA/RNA synthesis via xanthine, as also indicated by the decrease 
of guanine. 
Some metabolites, like acetylcarnitine and creatine, show up- as well as- down regulation 
within the five developmental stages. The observed trends of almost all of our identified fea-
tures is supported by the observations of previous publications[15][17]. Moreover, features 
that are indicated as new in table 1(arginine, acetylasparctic acid, carnitine, dimethylargi-
nine, dopamine, FAPy-adenine, indoleacetic acid, isovaleraldehyde, phosphoethanolamine, 
quinone, safrole, spermine dialdehyde, vinylacetylglycine) were exclusively found with our 
method and not in the aformentioned references. This indicates the potential of HR-DI-MS 
for metabolic profiling purposes.
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Deyolking
To obtain more insight in the biology of early embryogenesis, a series of deyolking experi-
ments were performed in order to zoom in on the localization of metabolism. Figure 5 shows 
several bar-plots of the group means of metabolites that were also (putatively) identifi ed in 
the previous section. Hypoxanthine and carnitine (metabolites which were discarded using 
our data cleanup steps (Supporting Figure 1)) showed a down-regulation trend during em-
bryogenesis).
Th e charts confi rm the same developmental trends as observed earlier. Because of the limited 
number of replicates that was measured (3 times) the statistical power is limited but ANOVA 
calculations showed that no signifi cant diff erence between the zygote part and the whole egg 
could be detected. Th is could indicate that most of the metabolites and most of the metabolic 
conversions take place in the zygote part. 
Figure 5: Bar-plots showing the mean of the diff erent embryonic location at the age of 3 hpf and 20 hpf. W=whole 
embryo; C=chorion membrane; Z=zygote part; NF=dechorionated non-fertilized embryo (=yolk). Th e y-axis repre-
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CONCLUDING REMARKS
Using our rapid metabolic fingerprinting method we were able to distinguish metabolic pro-
files of early developmental stages of zebrafish embryos. Interestingly, the onset of gene ex-
pression and the increase in energy requirement is reflected by the measured metabolome 
confirming that from a systems biology point of view metabolomics complements transcrip-
tomics. After data cleanup, only those features were selected that showed consistent behavior 
within each developmental stage resulting in 102 features. PCA revealed that periods of 1 
hour time shifts post fertilization could be differentiated from each other. In total 27 out of 
the 102 features were (putatively) identified. Although unambiguous identification is beyond 
the scope of our approach, identification on 6 of these 27 extracted features was pursued using 
standards and tandem MS. Several trends of the putatively identified metabolites are included 
and almost all of these findings are supported by previous publications. Moreover our me-
thod exclusively found several new features. By deyolking and dechorionating we showed the 
potential of this method to enable more in-depth studies on localization of metabolism. We 
conclude that HR-DI-MS is suitable for rapid metabolic profiling on zebrafish embryos. Ho-
wever, to improve robustness and obtain more high-quality features fast sample preparation 
methods are required.
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SUPPORTING INFORMATION
Supporting Figure 1: Boxplots of some of the discarded features due to our data cleanup steps.
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Three-phase Electroextraction: a 
new (online) sample purifi cation and 
enrichment method for bioanalysis
ABSTRACT
The migration, and at the same time enrichment of analytes from a liquid aqueous sample 
donor phase, through an immiscible organic solvent layer acting as a fi lter phase, into a liquid 
aqueous acceptor phase is enabled by the application of an electric fi eld between the donor 
and acceptor phase. The organic fi lter phase acts as a purifi cation fi lter which prevents e.g. 
proteins from migrating into the acceptor phase. Moreover, the composition of the organic 
fi lter phase infl uences the selectivity of the extraction. We show that analytes can be rapidly 
enriched from a 50 µL donor phase at the bottom of a sample vial, via an immiscible organic 
fi lter phase, into a 2 µL acceptor phase which consists of a droplet that is hanging from a 
(conductive) pipette tip in the organic fi lter phase. Acylcarnitines spiked to human plasma as a 
donor phase were extracted reproducibly with good linearity and a 10-fold improved limit of 
detection and, importantly, resulted in a stable, protein-free nanoelectrospray signal. Finally, 
a proof of principle towards the on-line integration in an automated nanoelectrospray-Direct 
Infusion-Mass Spectrometry platform has been realized. This makes 3-phase electroextraction 
(3-phase EE) a novel sample purifi cation and enrichment method, with straightforward on-line 
integration possibility. We envision that 3-phase EE will enable new possibilities using elec-
trokinetic sample pretreatment for fully automated, high-throughput bioanalysis purposes.
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INTRODUCTION
In the last decades the demand for rapid and accurate bioanalysis has increased. Effective 
sample preparation is an important step in the chemical analysis of biological samples. The 
main purposes of sample preparation are to (1) transport the analytes to a medium compa-
tible with the analytical instrument, (2) remove interfering matrix components and (3) con-
centrate the analytes, i.e. increase the concentration in the analysis solution compared to the 
concentration in the sample. Commonly used sample preparation methods include protein 
precipitation, liquid-liquid extraction and solid phase extraction[1]. For special applications 
special modifications of these approaches have been developed, such as e.g. single droplet 
microextraction (SDME) in where a hanging immiscible organic droplet is inserted in an 
aqueous sample in order to perform liquid-liquid extractions[2]. Although not often used yet, 
electrically driven sample pretreatment methods are increasingly reported such as electro-
membrane extraction (EME), electroextraction (EE)[3] and online preconcentration tech-
niques in capillary electrophoresis[4]. The latter, however, are not further considered in this 
article as for complex biosamples additional prior steps such as removal of plasma proteins 
is necessary. Sample preparation procedures based on electromigration are very promising, 
since a considerable part of the analytes in bioanalysis include compounds that are or can be 
charged (e.g. metabolites, xenobiotics and drugs) and thus are suitable for an electrophoretic 
approach. A recent three-phase elektrokinetic sample preparation method is EME[5]–[10]. 
In this technique, an organic solvent is held by capillary forces in the pores of a polymeric 
membrane. This membrane acts as a phase boundary between the aqueous donor and accep-
tor solutions. The analyte of interest is extracted from the aqueous donor phase on one side 
of the supported liquid membrane, through the organic membrane into the aqueous acceptor 
phase on the other side of the supported liquid membrane. This promising method has been 
successfully applied to the analysis of several pharmaceuticals in plasma and urine and also 
low-abundant peptides in human plasma[11], [12]. Another rapid electromigration-driven 
technique is 2-phase EE, which takes place in a two phase liquid-liquid system consisting of 
an aqueous and an organic phase, where an electric field causes the analytes to be extracted 
from the organic donor phase into the aqueous acceptor phase[13]–[15]. Ions in the organic 
phase are subjected to very high electric field strength due to low conductivity. As a conse-
quence, ions in the organic phase will migrate at high velocity, to be concentrated just after the 
liquid-liquid interface since the electric field of the aqueous acceptor is much lower. 2-phase 
EE has been successfully applied to several endogenous metabolites like peptides and carniti-
nes and also to standard solutions of leukotriens and catecholamines[16], [17]. 
Direct infusion-mass spectrometry (DI-MS) is a rapid, comprehensive analytical method wit-
hout the use of chromatography prior to MS. By using nanoelectrospray (nanoESI) instead of 
conventional ESI, ionization efficiency is enhanced, only a small amount (sub)-µL of sample 
is needed and ion suppression is reduced or even eliminated[18]. However, nanoESI emit-
ters (with internal diameters of typically a few µm) are susceptible to clogging due to pro-
tein precipitation, salt crystallization and dust/impurities which drives for an efficient sample 
preparation prior to analysis. Moreover, when a selective sample preparation procedure is 
chosen, ion suppression could be further reduced, since the enriched samples may contain 
less molecules when co-introduced in the MS. Additionally, coupling electrokinetic driven 
sample preparation techniques to nanoESI would be very suitable, since cations or anions are 
selectively migrating.
In this research paper we present 3-phase EE which enables fast migration of analytes from 
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phase by applying an electric fi eld between donor and acceptor, without the use of a mem-
brane like in EME. Moreover, in this system the analytes do not have to be dissolved and 
diluted in the organic phase prior to extraction, opposed to 2-phase EE. By locating the ac-
ceptor phase in a conductive pipette tip, a convenient implementation of the whole sample 
preparation procedure is realized, enabling easy integration with downstream applications. 
Extraction is realized by dispensing a hanging acceptor droplet out of the conductive pipette 
tip into the immiscible organic fi lter phase and applying an electric fi eld between both aque-
ous donor and acceptor phases (see Figure 1A). Compared to SDME our method is stagnant, 
but moreover the driving force is an applied electrical fi eld rather than a distribution coef-
fi cient, and by that, a more complete extraction can be achieved into such a small volume. Th e 
organic phase placed on top of the donor phase prevents proteins being transported into the 
acceptor phase and furthermore, by changing its composition, selectivity of the extraction can 
be tuned. In this way it is possible to extract analytes from a relatively large donor volume into 
a small droplet, since only (sub)-µL volumes are needed for performing nanoESI. In this pa-
per, we introduce and characterize the 3-phase EE process by studying the infl uence of extrac-
tion time and voltage, organic phase selectivity and protein elimination, and we demonstrate 
its potential in combination with mass spectrometry-based bioanalysis by the extraction of 
acylcarnitines spiked to plasma.
Figure 1:  Schematic illustration of (A) the 3-phase EE setup and (B) 3-phase EE followed by nanoESI-DI-MS analysis
EXPERIMENTAL SECTION
Chemicals
Methanol was from Biosolve (Valkenswaard, Th e Netherlands). Water (dH2O) was obtained 
from a Millipore high purity water dispenser (Billerica, USA). Ethylacetate (EtoAc), methyla-
cetate (MEtoAc), bis(2-ethylhexyl)phosphate (DEHP), crystal violet, bovine serum albumine 
(BSA), cytochrome C (Cyt C),  formic acid (FA), l-carnitine, acetyl-l-carnitine, propionyl-l-
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RESULTS AND DISCUSSION
The general operation of 3-phase EE is illustrated in Figure 1A. The sample (50 µL) was pip-
carnitine  dl-hexanoylcarnitine, dl-octanoylcarnitine, dl-decanoylcarnitine were  obtained 
from  Sigma-Aldrich (Steinheim, Germany). Deuterated butyryl-l-carnitine-d3 was obtained 
from CDN Isotopes (Pointe-Claire, Canada) and was used as an internal standard. Butyryl-
l-carnitine was bought from Larodan AB (Malmö, Sweden). All solvents were HPLC grade. 
Human plasma (EDTA) was obtained from healthy volunteers and combined in a plasma 
pool.
3-phase EE
All 3-phase EE results were obtained using an off-line setup (except for the experiments as 
described in the last paragraph). The equipment used for the off-line 3-phase EE is illustrated 
in Figure 1A. The DC power supply used had a voltage range from 0-2 kV, delivering a current 
of maximum 0.5 mA measured with a Keithley 485 picoammeter. A platinum wire (diameter 
= 0.28 mm) isolated with a Teflon sleeve was stripped from the end (1 mm) resulting in the 
electrode at the bottom of the donor phase. The pipette tip made from a conductive polymer 
(Advion, Ithaca, USA) was used as the counter electrode. A 10 µL syringe was connected to 
the pipette tip in order to aspire and dispense the acceptor phase. Off-line 3-phase EE was 
performed according to the following procedures; first the platinum electrode was inserted 
into a 500 µL eppendorf tube. The donor phase was pipetted (50 µL) into the eppendorf tube, 
followed by 150 µL of the immiscible organic filter phase as a layer above. The organic phase 
was saturated with dH2O in order to conduct ions and to prevent the acceptor droplet from 
dissolving. The pipette tip, filled with 2.5 µL aqueous acceptor phase, was inserted into the 
immiscible organic filter phase after which 2 µL was dispensed so that a hanging droplet at the 
tip was created and a voltage (typically 140V) was applied for 3 minutes (or stated otherwise). 
After 3-phase EE, the voltage was switched off and the 2 µL acceptor droplet was aspired back 
into the pipette tip and transferred for analysis (Figure 1B). The organic filter phase used was a 
composition of EtoAC:MEtoAC (3:2) or stated otherwise in the selectivity experiments. Using 
this composition, the organic filter phase was immiscible with the donor and acceptor phase. 
In all experiments the donor phase consisted of 33% methanol (to decrease conductivity, thus 
increase the electric field strength) and in case of the plasma experiments also 5% FA was ad-
ded to reduce plasma protein binding of the model analytes. The acceptor phase consisted of 
33% methanol (to enhance ionization efficiency in ESI) and 5% FA (to anticipate on possible 
pH drop due to electrochemical reactions). Moreover, using these aqueous compositions, the 
essential condition of immiscibility with the organic filter phase was still maintained. The 
internal standard was spiked to the acceptor phase prior to 3-phase EE.
Mass Spectrometry
The 3-phase electroextraction analyses were performed by DI-MS in the positive mode using 
an automated nanoESI (Advion Triversa NanoMate, Ithaca, USA) source coupled to a LTQ-
Orbitrap XL (Thermo Fisher Scientific). In the off-line setup, the 2 µL acceptor was pipetted 
into Eppendorf 384 well plate in order to be infused with a back pressure of 0.25 psi and an 
electrospray voltage of 1.55 kV in the positive mode.
The inlet capillary temperature was 120 °C, the capillary voltage and the tube lens voltage was 
30 and 100 V, respectively. Mass spectra were recorded at a resolution of 30,000 and 10-20 
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peted into an Eppendorf tube and 150 µL of the immiscible organic fi lter phase was placed on 
top as a second layer. For a visual proof of concept of the general operation, an experiment was 
conducted using a 10 µM crystal violet (cationic dye) standard in the donor phase. Th e result 
before and aft er 3-phase EE is shown in Figure 2. Aft er 3 minutes the donor phase appeared 
depleted of crystal violet, whereas the acceptor droplet was enriched with crystal violet (see 
Movie 1, Supporting Information). In addition the movie shows that in the acceptor droplet 
the extracted crystal violet appeared to distribute homogeneously within seconds caused by 
diff usion and convection: this shows that a possible problem due to improper mixing of ana-
lytes and internal standards spiked to the acceptor phase prior to 3-phase EE does not occur.
Two processes play an important role in 3-phase EE: (1) Th e driving force in 3-phase EE is the 
applied electrical fi eld between the donor and acceptor phase. Th erefore, to enable 3-phase 
EE, the whole system comprising the donor, organic fi lter and acceptor phase should serve as 
an electrical circuit. Represented in a simplifi ed manner, the electrical circuit model consists 
of three serial resistors representing the three phases. Since the resistance associated with the 
organic phase is dominant, it limits the current through the system. In order to fi ne-tune the 
system, the conductivity of the phases can be altered by changing the composition/polarity. 
Th e donor phase consisted therefore of 33% methanol: the addition of methanol decreased its 
conductivity and thus increased its electric fi eld and the analyte velocity in the donor phase 
during 3-phase EE. 
Initially, during 3-phase EE, ions migrate from the donor phase towards the organic fi lter 
interface at a velocity imposed by their electrophoretic mobility (µ) and the electric fi eld 
strength (E) in the donor phase[19]–[21]. Once arrived in the organic fi lter phase, ions are 
subjected to a much higher electric fi eld strength due to the low conductivity. As a conse-
quence, ions in the organic phase migrate at a higher velocity and concentrate just aft er the 
organic fi lter-acceptor interface, as the electric fi eld strength in the aqueous acceptor phase is 
much lower. A practical limitation of the applied electric fi eld strength is the stability of the 
hanging droplet. In our experiments at voltages higher than 250 V the droplet is pulled off  due 
to electrostatic force. Th erefore we used 140 V to obtain reproducible results, to be sure of not 
losing the droplet even at extraction times up to 10 minutes. 
(2) Th e distribution of the analytes based on the partition coeffi  cient K1 at the donor-organic 
fi lter interface plays an important role in 3-phase EE as well. Due to the low electric fi eld 
strength in the donor phase the ions will arrive at the interface at moderate velocity, therefore 
K1 determines the transport rate of the ions from the donor into the organic fi lter phase. In 
Figure 2: Video stills of crystal violet subjected to 3-phase EE at (A) t=0, no voltage applied, (B) t=3 minutes aft er 
applying the voltage.
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addition, in our setup the total migration length (thus migration time) in the donor is only a 
few millimeters therefore further minimizes the influence of electrophoretic mobility on the 
transport into the organic filter phase. The partition coefficient K2 at the organic filter-accep-
tor interface does only play a role when the analytes are rather apolar since ions are crossing 
this interface at high velocity due the high electric field strength in the organic filter phase. 
As a consequence for the rather polar analytes K1 and the rather apolar analytes K2 causes the 
selectivity of the system, which is elaborated in the next paragraphs.
Electrochemical reactions of analytes could occur at the surfaces of both electrodes. In all 
the experiments no significant gas formation was observed with the extraction voltage used, 
except during the longest extraction times of 10 minutes. This was tackled by aspiring the 
formed gas bubble into the pipette tip, but was not required at the conditions finally chosen.
Calculation of Enrichment.
The enrichment factor EF of 3-phase EE was calculated according to equation 1 for each 
analyte:
       (1)
where the normalized intensity was obtained by dividing the absolute intensity of the extrac-
ted analyte by the absolute intensity of the internal standard spiked to the acceptor phase 
prior to 3-phase EE. The normalized response of the donor phase was obtained by spiking 
that phase with internal standard and infuse it without the 3-phase EE step. To justify these 
calculations, the absolute intensities of the internal standard were checked; they did not sig-
nificantly change during experiments because of possible electrochemical degradation or dif-
fusion into the organic filter phase. For a good comparison, the donor was analyzed under the 
same conditions as the acceptor.
Effect of extraction time and voltage on enrichment
Seven carnitines with increasing size (and decreasing electrophoretic mobility[22]) and de-
creasing polarity were selected as model analytes (Supporting Table 1). Using these model 
analytes the dominant influence of the polarity of the analytes and thus the partition coef-
ficient K1 and K2, in 3-phase EE could be demonstrated.  In these experiments, the enrich-
ment factor of the model analytes was studied as a function of 3-phase EE time and voltage. 
Enrichment in this setup was achieved by extracting the analytes from 50 µL donor to a 2 µL 
acceptor droplet. As a consequence the theoretical maximum enrichment factor was 25. The 
carnitines were always charged, since they are quaternary ammonium compounds. The ac-
ceptor phase was spiked with 1 µM butyrylcarnitine d3 which was used as an internal standard 
for normalization. Experiments were performed with extraction times of 0.5, 1, 2, 3, 5 and 10 
minutes at a voltage of 70 (Figure 3A) and 140 V (Figure 3B).
Applying an electrical potential difference of 140 V, several analytes were enriched close to 
the maximum enrichment factor, already within 3 minutes. In order to explore the depletion 
of the donor phase, three subsequent extractions were performed on the same donor and or-
ganic phase, refreshing only the acceptor phase after each extraction. These results show that 
decanoyl and octanoylcarnitine were hardly present after the first extraction indicating that 
for these analytes the donor was almost depleted. Another control experiment was conducted 
for transport based on 3 minutes of passive diffusion only, without applying the electrical po-
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transport speed from donor to acceptor phase was improved dramatically upon application 
of the voltage.
During the fi rst 3 minutes the extraction rate (Δenrichment factor/Δextraction time) was 
higher at 140 V than when applying 70 V (Figure 3) which can be explained by the diff erence 
in the driving electrical fi eld strength. In the fi rst 3 minutes also the infl uence of both K1 and 
K2 is revealed: the most polar acylcarnitines (carnitine to hexanoylcarnitine) are extracted 
with an increased extraction rate as the polarity of the analyte increases, imposed by K1. Th ese 
results confi rm that the partition coeffi  cient K1 across the aqueous-organic fi lter interface is 
the limiting factor for this settings, since hexanoyl-and octanoylcarntine were extracted faster 
than the smaller carnitines, while their electrophoretic mobilities are lower. For the most apo-
lar carnitine (decanoylcarnitine) the extraction rate decreased with an increase in apolarity, 
which is caused by the infl uence of K2, which becomes important for more apolar compounds. 
Aft er 3 minutes the three most apolar carnitines started to decrease over time. Th is decrease 
was caused by back extraction from the acceptor phase into the organic fi lter phase, imposed 
by K2. Th is is explained by the fact that the electrical fi eld density is not homogeneously dis-
tributed around the acceptor droplet being signifi cantly less dense at the top surfaces of the 
acceptor droplet (see fi nite element simulation, Supporting Figure 1). Analytes could reach 
the top of the acceptor droplet by diff usion and/or possible convection. To test this hypothe-
sis, two follow-up experiments were performed. First we spiked 10 µM of the carnitines to the 
acceptor phase and using a blank donor when no electrical fi eld was applied, more than 95% 
of the three most apolar carnitines were diff used into the organic fi lter phase aft er 10 minutes 
of extraction, solely caused by partition coeffi  cient K2. Secondly this experiment was repeated, 
but an electrical fi eld was applied. Now the three most apolar carnitines were back extracted 
into the organic fi lter phase to about 50% of their total amount, which is comparable with the 
actual decrease we observed during 3-phase EE aft er 10 minutes of extraction. Other possible 
causes for the decrease such as electrochemical degradation and adhesion to the pipette tip 
were excluded (data not shown). 
Th ese characterization results indicate that for each application with its associated target ana-
lytes an optimal organic fi lter phase should be chosen (see next paragraph). Probably, possible 
back-extraction can be reduced by increasing the surface of the bottom electrode of the well 
and optimizing the geometry of the setup.
Figure 3: Average enrichment factor (n=3) versus extraction time of the 7 model analytes applying (A) 70 V and (B) 
140 V.
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Infl uence of the organic fi lter phase composition on enrichment
To further show the infl uence of the partition coeffi  cient K1 for 3-phase EE, experiments with 
diff erent organic fi lter phase compositions were conducted and the enrichment factor was 
calculated. By mixing organic solvents and by adding an ion pair modifi er, the polarity of the 
organic fi lter phase, therefore K1 and K2, can be changed to tune selectivity of 3-phase EE. By 
adding an ion pair modifi er (e.g. DEHP), the organic fi lter phase becomes more accessible 
for ions and therefore making K1 more favorable towards polar analytes. Organic fi lter phases 
with increasing polarity were tested: EtoAC, EtoAC:MEtoAC (3:2), EtoAC+1% DEHP and 
EtoAC+5% DEHP. Th e acceptor phase was spiked with 1 µM butyrylcarnitine d3 as an inter-
nal standard for normalization purposes. Figure 4 shows that by increasing the polarity of the 
organic fi lter phase, the optimum analyte apolarity shift s to lower values while seemingly nar-
rowing the polarity window, and hence increasing selectivity.  It can be observed that by using 
pure EtoAC the more apolar carnitines were most enriched, while transport of the smallest 
polar analytes was (almost) disabled at the same time due to the partition coeffi  cient K1. In 
contrast, by adding 5% of the modifi er DEHP, the extraction was more selective towards the 
polar carnitines and the largest (apolar) decanoyalcarnitine was hardly enriched. Th ese fi n-
dings lead to the important conclusion that selectivity in 3-phase EE can be tuned. As a conse-
quence, the selection of the composition of the organic fi lter phase should be tuned according 
the analytes of interest. Th ese observations are in agreement with applications of EME which 
reported that the chemical composition of the membrane infl uenced selectivity[3].
Figure 4: Average enrichment factor versus apolarity (expressed as log P) of the analyte and the infl uence of the 
organic fi lter phase ((n = 3), all RSD<15%).
Sample purifi cation
In the following experiments an academic test solution (500 µg/mL) of a large model protein 
BSA (MW = 66.5 kDa) and and a smaller model protein Cyt C (MW = 12 kDa) was tested. 
BSA was chosen because albumine is the most predominant (55%) blood plasma protein[23] 
and Cyt C was added to assess the behavior of small proteins in the system. Th e protein 
standard solutions were subjected to 3-phase EE-DI-MS and was compared to DI-MS of the 
donor phase before 3-phase EE to which 5% FA added. Supporting Figure 2A shows that the 
MS spectrum of the BSA standard consists of a broad BSA envelope centered around 1500 
m/z, obtained for the analysis of the donor phase which is not observed with 3-phase EE-
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standard consists of two smaller envelopes centered around 1537 m/z and 1752 m/z, opposed 
to the MS spectrum of the 3-phase EE extract (Supporting Figure 2D). These results show that 
the large BSA as well as the much smaller Cyt C are not transported into the acceptor phase 
during 3-phase EE. These results confirm the same selectivity principle (partition coefficient 
K1) discussed in the previous paragraph: since the proteins do not dissolve (precipitation) 
in the used organic filter phase, they did not pass the donor-organic filter interface during 
3-phase EE. Additionally, in the next paragraph the same mass range was scanned for the pre-
sence of proteins in spiked plasma. In these experiments protein precipitation was observed 
between the donor and organic filter phase. 
Spiked plasma
To finish the evaluation of 3-phase EE, the acylcarnitines were spiked into samples of a pool 
of human blood plasma. By spiking the carnitines the plasma was diluted 10-fold in 33% 
methanol and 5% FA (pH=2.0), in order to make a valid comparison with the academic test 
mixture experiments. After dilution no protein precipitation was observed at this level of 
MeOH and FA. Subsequently the samples were subjected to 3-phase EE. The model analytes 
were effectively extracted from human plasma (Table 1). These results show that 3-phase EE 
can be used for the enrichment of complex samples. For all model analytes slightly lower en-
richment values were obtained from human plasma samples compared with those of the aca-
demic test solution (Figure 4). This can possibly be explained by the plasma protein binding 
of the model analytes. Marzo et al. reported that carnitine and its short-chain esters did not 
interact with plasma proteins while octanoylcarnitine interacted to a poor extent (12-30%), 
and the larger carnitines were completely bound to plasma proteins[24]. Acidification of the 
donor phase with 5% FA appeared to be necessary, as without little enrichment was observed: 
upon acidification proteins are protonated, resulting in less binding of the model analytes. 
Since the plasma samples had high viscosity, high protein content and are more complex than 
the previously examined standard standard solutions, longer extraction times were needed 
to obtain higher enrichment (Figure 4). After 9 minutes of extraction, the smallest carnitines 
were enriched approximately 3x more (Table 1), whereas the largest carnitine did not benefit 
from the longer extraction time, due to the back extraction process into the organic phase as 









aAll RSD <15%; * = corrected for the endogenous 
level (Table 2).
Table 1: Enrichment values of the carnitines (500 nM equimolar) spiked in human plasma, (n = 3)a, 
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As a reference the plasma donor phase spiked with 500 nM of carnitines was analyzed di-
rectly. This resulted in an unstable nanoelectrospray signal possibly caused by the abundant 
plasma proteins which was also visible as a broad envelope in the 1000-2000 m/z range, and 
moreover only a few model analytes could be detected close to their limit of detection. These 
findings demonstrated the potential of 3-phase EE as a rapid and effective sample cleanup and 
enrichment technique for bioanalysis. 
Calibration curves were obtained by spiking the acylcarnitines (0, 10, 50, 100, 500 and 1000 
nM) and 1 µM butyrylcarnitine d3 as an internal standard to the plasma and for carnitine (0, 
10, 50, 100, 500, 1000 and 5000 nM). The performance results are summarized in Table 2.
analyte Linearity (R2) 10-
1000 nM
LOD donor solution 
(nM)
LOD blood* (nM) Concentration 
blood* (µM)
carnitine 0.999 - - 26
acetylcarnitine 0.997 - - 0.8
propionylcarnitine 0.994 9 90 x
butyrylcarnitine 0.989 29 290 x
hexanoylcarnitine 0.987 33 33 x
octanoylcarnitine 0.995 28 280 x
decanoylcarnitine 0.992 29 290 x
a x< LOD; - = not possible to determine; * the donor solution was obtained by diluting 1:10, the LOD for blood and 
the concentration in blood was obtained by multiplying the concentrations obtained in the donor with 10. LOD 
was determined by (Yblank + 3SDblank - interceptresponse curve)/sloperesponse curve.
Linear behavior of 3-phase EE was observed by measuring the response of the analyte vs. their 
concentration over 2 orders of magnitude. The R2-values of the linear regression line ranged 
from 0.987 to 0.999 for the compounds tested. Limits of detection[25] were in the nM range 
for most of the tested compounds and were improved 10-fold compared to the DI-MS ana-
lysis of the donor phase. The limit of detection of carnitine and acetylcarnitine could not be 
accurately determined, since no measurements could be done at levels close to the detection 
limit due to the relatively high endogenous levels[26].  In the future the overall limit of detec-
tion can easily be improved by using a larger donor volume and/or using a smaller acceptor 
volume, possibly at the cost of a longer extraction time. Also, future research will be directed 
to optimizing the organic filter phase composition to achieve a more efficient extraction. The 
repeatability of the 3-phase EE measurements in plasma showed RSD values below 15%, and 
in the future this can most likely be improved by automation.
The endogenous levels of free carnitine and acetylcarnitine were in agreement with litera-
ture[27], [28]. Interestingly, and also as expected, many other plasma components were ob-
served in the MS spectra and by putative identification (based on exact mass), among others, 
several amino acids were annotated such as leucine and phenylalanine. This suggests that 
the used organic filter phase was also suitable for the 3-phase EE analysis of many amino 
acids. Future research has to be done in order to characterize 3-phase EE for nonpermanently 
charged compounds like amino acids and drugs.
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Toward online 3-phase EE-nanoESI-DI-MS: proof of principle.
In the final experiments the first steps of the integration of 3-phase EE into a fully automated 
system using an automated nanoESI robot (Triversa NanoMate) were made.
A 96 polypropylene well plate was modified by removing the bottom of some of the wells and 
replacing it by a stainless steel plate which functioned as the anode (Supporting Figure 3). 
The mandrel of the NanoMate, which grabs the pipette tip and which is also electrically con-
nected to the grabbed pipette tip, functioned as the cathode. Both electrodes were connected 
to a voltage source.
150 µL of the donor academic test mixture of 500 nM carnitines was pipetted in one of the 
wells containing a bottom electrode, followed by 250 µL of the organic filter phase on top.  A 
sequence was programmed in the NanoMate Chipsoft software which (1) aspired 1 µL of the 
acceptor phase from a certain well, (2) moved the pipette tip to the extraction well in which it 
was positioned in the organic filter phase, (3) dispensed a 1 µL droplet and waited 3 minutes 
to perform the extraction, (4) subconsequently aspired the acceptor droplet back into the pi-
pette tip and (5) performed nanoESI. The required extraction voltage was only 55 V in order 
to get the same extraction currents as for the off-line experiments and was manually turned 
on and off using the external voltage source, but in the future this can also be automated. The 
first proof of principle result is shown in Supporting Table 2 which revealed an about 5-fold 
increase of the enrichment factor, compared to the off-line results in Figure 4. This increase in 
the enrichment factor can be explained by the 2-fold smaller acceptor volume and the 3-fold 
larger donor volume. These results demonstrate the potential of 3-phase EE as an easy auto-
mated, high-throughput sample preparation method. Further research and development has 
to be done on improving the on-line setup into a fully automated, high-throughput screening 
platform.
CONCLUSIONS AND OUTLOOK
In this paper, we demonstrated the fast and selective electromigration of analytes from an 
aqueous sample through an immiscible organic filter phase into an aqueous acceptor phase. 
We demonstrated that this technique, which we described as 3-phase electroextraction 
(3-phase EE), can be efficiently used for sample purification in bioanalysis, since the organic 
phase prevents proteins from being transported into the acceptor phase. Selectivity can be 
tuned by proper selection of the composition of the organic filter phase, being an attractive 
feature of 3-phase EE. Enrichment of the analytes was demonstrated by extracting them from 
a 50 µL sample into a small 2 µL acceptor droplet.  Using academic test solutions, several of 
the model compounds were enriched close to the expected enrichment maximum, already 
within 3 minutes. Moreover, 3-phase EE was found to be suitable for extracting and enriching 
spiked carnitines from human plasma samples. 3-phase EE coupled to direct infusion-MS of 
plasma showed a good linear response over two orders of magnitude and improved detection 
limits and importantly, resulted in a stable protein-free nanoelectrospray-MS signal. Since the 
maximum enrichment factor is proportional to the volume of the donor phase and inversely 
proportional to the volume of the acceptor phase, 3-phase EE could easily be used to achieve 
a 100-fold or more enrichment. In addition, future research will be done on optimizing the 
composition of the organic filter phase, on 3-phase EE geometries in order to maximize fast 
enrichment and on extending the type of analytes.
Finally, proof of principle of the integration of 3-phase EE in a commercially available on-line 
robotic nanoESI-DI-MS system was achieved. Next to coupling to DI-MS, 3-phase EE can 
also be integrated in other downstream (separation) applications such as LC and CE. Thanks 
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to its combination of sample purification, selective enrichment of analytes from biofluids to 
an aqueous phase and the simplicity of the setup, 3-phase EE holds the promise to become a 
core sample preparation module in fully automated, high-throughput bioanalysis.
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Supporting Table 1: Carnitines with increasing mass and increasing apolarity.
Supporting Table 2: Enrichment factor of online 3-phase EE on an academic test mixture of 500 nM acylcarnitines 
(n = 1).
Supporting Figure 1: Finite element simulation of the off -line 3-phase EE setup showing the electric fi eld density 
distribution. As depicted, the electric fi eld density is signifi cantly lower at the top surface of the acceptor droplet, 
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Supporting Figure 2: Averaged mass spectra of (A) BSA standard (500 µg/mL) (B) 3-phase EE of BSA standard (500 
µg/mL) (C) Cyt C standard (500 µg/mL) (D) 3-phase EE of Cyt C standard (500 µg/mL)
Supporting Figure 3: Photo of a modifi ed 96 polypropylene well plate with an electrode at the bottom of three well-
rows integrated in the automated nanoESI robot.
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Chapter 5
Gas Pressure Assisted Micro-Liquid-
Liquid Extraction coupled Online to 
Direct Infusion Mass Spectrometry: a 
New Automated Screening Platform for 
Bioanalysis. 
ABSTRACT
In the fi eld of bioanalysis there is an increasing demand for miniaturized, automated and 
robust sample pretreatment procedures which can be easily connected to direct-infusion 
mass spectrometry (DI-MS) in order to allow the high-throughput screening of drugs and/or 
their metabolites in complex body fl uids like plasma. Liquid-Liquid extraction (LLE) is a com-
mon sample pretreatment technique often used for complex aqueous samples in bioanalysis. 
Despite signifi cant developments that have been made in automated and miniaturized LLE 
procedures, fully-automated LLE techniques allowing high-throughput bio-analytical studies 
on small-volume samples using direct infusion mass spectrometry, have not been matured 
yet. Here, we introduce a new fully-automated micro-LLE technique based on gas-pressure 
assisted mixing followed by passive phase separation, coupled online to nanoelectrospray-
DI-MS. Our method was characterized by varying the gas fl ow and its duration through the 
solvent mixture. For evaluation of the analytical performance four drugs were spiked to human 
plasma, resulting in highly acceptable precision (RSD down to 9%) and linearity (R2 ranging 
from 0.990 to 0.998). We demonstrate that our new method does not only allow the reliable 
extraction of analytes from small sample volumes of a few microliters in an automated and 
high-throughput manner, but also performs comparable or better than conventional offl ine 
LLE in which the handling of small volumes remains challenging. Finally, we demonstrate the 
applicability of our method for drug screening on dried blood spots showing excellent linea-
rity (R2 of 0.998) and precision (RSD of 9%). In conclusion, we present the proof of principe of 
a high-throughput screening platform for bioanalysis based on a new automated micro-LLE 
method, coupled online to a commercially available nano-ESI-DI-MS. 






In the last decades there has been a strong demand for high-throughput MS-based tech-
nologies for bioanalytical and pharmaceutical screening studies such as in drug discovery 
and development[1]. Direct infusion-mass spectrometry (DI-MS) is an analytical technique 
which is in principle very suitable as a rapid and global high-throughput screening platform 
since it does not include often time consuming separation methods prior to MS detection[2]. 
However, as a consequence, DI-MS is susceptible to potential ion suppression effects due to 
interfering, co-eluting matrix components in the samples, especially when using electrospray 
ionization (ESI)[3]. By employing nano-electrospray (nanoESI) ionization instead of conven-
tional ESI, the ionization efficiency can be somewhat improved as ion suppression is conside-
rably reduced under low flow-rate conditions [4]. However, nano-ESI nozzles (with diameters 
of typically a few µm) are prone to clogging as a result of protein precipitation, salt crystal-
lization and dust/impurities which asks for an efficient sample pretreatment prior to analysis. 
Moreover, when an effective sample pretreatment procedure is carried out, ion suppression 
may be further reduced, since the extract contains fewer molecules when co-introduced into 
the MS. Plasma is a complex sample due to the presence of proteins, salts and a wide range of 
(endogenous) metabolites with a chemistry which may be similar to the analytes of interest 
and/or causing ion suppression. Therefore, an efficient sample pretreatment procedure for the 
clean-up and selective extraction of the compounds of interest is often required for the relia-
ble analysis of drugs in complex samples like plasma by DI-MS-based approaches. 
With sample pretreatment being one of the major challenges in a typical (DI)-MS-based 
screening pipeline, significant progress has been made in the improvement of sample pre-
treatment procedures over the past few years[5]. New developments for sample pretreatment 
methods are often directed towards simplification, automation, miniaturization, integra-
tion in well-plate formats,  more environment friendly and specificity enhancements of the 
clean-up and enrichment process[6][7]. Liquid-liquid extraction (LLE), next to solid-phase 
extraction (SPE), is a common sample pretreatment technique[8] which can be used to ex-
tract relatively apolar molecules from a complex aqueous biological sample phase into an im-
miscible organic phase. After the LLE procedure both fractions, containing polar and apolar 
compounds, can then be independently analyzed. Although LLE techniques are commonly 
used, their use in online systems is much less than e.g. SPE techniques. Moreover, most of the 
reported LLE systems are rather difficult to automate especially for small volume-samples of a 
few microliters due to the fact that conventional LLE  requires a mixing and often a centrifu-
gation step which are challenging to automate (e.g. in a multi-well format)[9]. Off-line sample 
pretreatment can be considered a limiting step for high-throughput bioanalysis of especially 
small sample volumes, indicating a clear need for on-line sample pretreatment procedures to 
shorten the total sample handling and analysis time and to reduce the possibilities for errors. 
In addition, when samples in a well plate are processed in a parallel manner prior to analysis, 
the handling time per sample is slow and variable and evaporation of volatile solvents and 
analyte degradation could be an issue.
An emerging trend in the field of biomedical and pharmaceutical analysis is to analyze drugs 
in limited sample amounts, such as dried blood spots (DBS) and plasma of mice (especially in 
the case of longitudinal studies the amount of plasma which can be collected from the same 
mouse, usually via the tail, is only a few microliters)[1]. Therefore, miniaturization and auto-
mation of the sample pretreatment procedure is needed in order to allow the analysis of drugs 
in these types of small samples in a very effective and high-throughput manner by MS. So 
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far, various miniaturized LLE strategies have been developed such as liquid-phase microex-
traction (LPME) approaches [7]. In LPME, extraction generally takes place from an aqueous 
sample phase into a small amount of a water-immiscible organic acceptor phase, and reducing 
the acceptor-to-donor ratio with typical enrichment factors between one and two orders of 
magnitude[10]. LPME has been developed in a variety of configurations such as single drop 
microextraction (SDME)[11][12][13], headspace LPME[14], hollow fiber (HF)-LPME[15]
[16], continuous flow LPME[17], solvent bar microextraction[18][19], dispersive liquid-li-
quid microextraction (DLLME)[20][21] and parallel artificial liquid membrane extraction 
(PALME) [22][23], among others. However, most of these LPME methods need a form of 
(off-line) agitation in order to get efficient extractions which will make it less straightforward 
to implement in a fully-automated high-throughput analytical platform. Interestingly, the on-
line coupling of (micro)LLE procedures to nanoESI-DI-MS has, to our knowledge, not been 
explored yet. 
Here, we present the proof principle of a new and simple approach to miniaturized and auto-
mated LLE, so-called gas pressure assisted micro liquid-liquid-extraction (GPA-µLLE) cou-
pled online to nanoESI-DI-MS. Rapid extraction is realized by dispensing an aqueous sample 
phase into DCM after which both phases are mixed thoroughly by applying nitrogen gas 
pressure and flowing gas through the liquid phases. After passive settling of the phases under 
the mentioned conditions, 2 µL of DCM is aspired and consecutively analyzed with nanoESI-
DI-MS. As a consequence, our method is easy to automate as it bypasses the need for off-line 
vortexing and centrifugation as is the current standard. Furthermore, as GPA-µLLE is per-
formed in 384-well plate, it is compatible with handling small sample volumes. In addition, 
by the integration of GPA-µLLE in a commercially available nanoESI robot, GPA-µLLE is 
coupled on-line to DI-MS making it very suitable for a high-throughput screening platform. 
Moreover, in our method, every sample is sequentially processed which results in a short and 
constant handling time per sample which is also very suitable for volatile solvents such as 
DCM. The GPA-µLLE procedure is characterized by studying the effect of the gas pressure 
and its duration on the recovery of test analytes. Subsequently, the potential of micro-LLE 
coupled online to nanoESI-DI-MS for the extraction and screening of drugs from human 
plasma is demonstrated. A comparison between GPA-µLLE and conventional (off-line/ma-
nual) LLE is made, as well as with ‘dilute and shoot’ methods. Finally, the utility of GPA-µLLE 
for the screening of lidocaine in a DBS sample is shown.
EXPERIMENTAL SECTION
Chemicals and materials
Water (H2O) and methanol was bought from Actu-All Chemicals (Randmeer, The Nether-
lands). Dichloromethane (DCM), crystal violet, fluorescein, lidocaine, propranolol, ver-
apamil, loperamide were obtained from Sigma-Aldrich (Steinheim, Germany). Diltiazem 
and chlorpromazine were from Sigma-Aldrich (Steinheim, Germany) and used as internal 
standards. Diltiazem was used for normalizing lidocaine and chlorpromazine was used for 
normalizing propranolol, verapamil and loperamide. All solvents were HPLC grade. Human 
plasma (heparin) and whole blood (heparin) were obtained from adult healthy volunteers. 






All the GPA-µLLE-DI-MS steps were programmed and performed in a Nanomate robot (Ad-
vion Triversa NanoMate, Ithaca, USA) in a fully automated manner, except of the prefilling 
of the well-plate. The steps used for GPA-µLLE are illustrated in Figure 1. The GPA-µLLE was 
performed according to the following procedure:  in a 384-well plate, two adjacent wells were 
prefilled with 14 µL aqueous sample (blue), consisting of 14-fold diluted plasma dissolved in 
71.5% methanol, and 10 µL DCM (orange) as an immiscible organic phase (Figure 1A). The 
aqueous sample phase consisted of 71.5% methanol which was based on a Bligh and Dyer[24] 
extraction in order to get an efficient extraction and protein precipitation. Moreover, after 
mixing, some of the methanol and H2O was dissolved in the DCM, making it suitable for 
nanoESI (pure DCM could not be electrosprayed). The aqueous phase was dispensed into 
the DCM from the bottom of the well (Figure 1B). Thorough mixing of both phases was ac-
complished by applying a gas pressure of nitrogen (in our system typically 0.5 psi, or stated 
otherwise) on a pipette tip (inner diameter of 0.5 mm) inserted at the bottom of the well for 
a certain time duration (typically 20 sec, or stated otherwise), see Figure 1C. During a short 
period of time (90 seconds), both phases were allowed to settle and separate (Figure 1D) 
and, subsequently, 2 µL of the DCM phase was aspired into a new pipette tip (Figure 1E) and 
transferred for analysis (Figure 1F). 
Comparison with ‘dilute and shoot’ methods
The ‘dilute and shoot’ experiment was carried out after spinning down the precipitated pro-
teins of the aqueous phase. After centrifugation, the supernatant mixture was directly infused 
into the MS using nanoelectrospray ionization using the same MS settings as for the direct 
infusion of the DCM extract after GPA-µLLE. 
Dried blood spots
20 µL of whole blood spiked with lidocaine was pipetted on standard blood spot cards ob-
tained from RIVM (the Netherlands). The dried blood spots (DBS) were punched out (3 mm 
diameter) from the middle of the spot and inserted into the bottom of a 384-well plate, which 
was placed  in the NanoMate. 20 µL of aqueous solvent (71.5% methanol) including 100 nM 
diltiazem as an internal standard was added to the DBS and 30 minutes of passive extraction 
was chosen prior to GPA-µLLE-DI-MS.
Mass spectrometry
The GPA-µLLE on-line coupled  to DI-MS (positive mode) were carried out using an auto-
mated chip-based nanoESI (Advion Triversa NanoMate, Ithaca, USA) source coupled to a 
LTQ-Orbitrap XL (Thermo Fisher Scientific). In the NanoMate ChipSoft software (version 
4.3.3.1108) the Advanced User Interface (AUI) was enabled in order to program and preform 
all the steps needed for µ-LLE. Finally, a 2 µL extract was aspired and infused with a back 
pressure of 0.4 psi and an electrospray voltage of 1.47 kV in the positive mode. The well-plate 
was set to a temperature of 4°C in order to reduce the evaporation rate of DCM and to ensure 
a fixed temperature. At this temperature no visible loss of DCM was observed within the 
experimental time of around 2 minutes. To further control evaporation, a well-plate cover 
foil could be used. The inlet capillary temperature was 120°C, the capillary voltage and the 
tube lens voltage was 30 and 100 V, respectively. The automatic gain control and injection 
waveforms were enabled. Mass spectra were recorded at a resolution of 100,000 using one 
microscan and 10-20 scans were averaged in order to further analyze the data. The response 
of the drug compounds analyzed was normalized with the appropriate internal standard by 
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calculating the ratio of intensity of the drug and intensity of the internal standard.
Figure 1: Schematic illustration of the individual steps of the GPA-µLLE method. (A) A 384 well plate is prefi lled 
with an aqueous methanol-water (blue) sample and dichloromethane (DCM) (orange). (B) 14 µL of the AQ sample 
is pipetted into the bottom of the DCM layer. (C) Vigorous mixing is achieved by applying nitrogen gas pressure 
onto the pipette tip while the pipet is immersed in the liquid. (D) Aft er mixing, both phases are allowed to settle and 
separate. (E) 2 µL of the DCM phase is pipetted and (F)directly infused into MS using nanoelectrospray ionization.
RESULTS AND DISCUSSION
In this section the proof of principle of GPA-µLLE is demonstrated followed by the characteri-
zation of two important parameters, i.e. the gas fl ow through the liquid mixture controlled by 
the applied gas pressure and its duration. Next, the performance of GPA-µLLE was evaluated 
and compared to conventional LLE and ‘dilute and shoot’ methods. Finally the utility of GPA-
µLLE applied to DBS for drug screening was demonstrated. 
Proof-of-principle of GPA-µLLE 
Th e general working principle of GPA-µLLE is illustrated in Figure 1. For a visual proof of 
principle of the general operation, an experiment was conducted using a (green) mix of 59 µM 
crystal violet and 200 µM fl uorescein as an aqueous sample. Th e results are shown in Figure 
2. Th e aqueous sample was aspired from its well and dispensed at the bottom of the prefi lled 
DCM well aft er which a bi-phasic system was generated (Figure 2B). Aft er this step already 
some, but limited, extraction of crystal violet into the DCM could be observed, whereas, aft er 
10 seconds of nitrogen gas-pressurized mixing (Figure 2C), the majority of the crystal violet 
was extracted. Aft er 90 seconds the two phases were settled into a bi-layer system (Figure 2E). 





During the mixing step the surface contact between both phases is enhanced and therefore 
the extraction effi  ciency is improved. From Figure 2D (taken 2 seconds aft er mixing) it can be 
seen that during mixing an emulsion of the organic phase and the aqueous phase was formed. 
Furthermore, the precipitated proteins are distributed in the aqueous phase, but not in the 
organic DCM phase, as can be observed in Figure 2F.
Figure 2 : Video stills showing the proof of principle of GPA-µLLE of a plasma sample: (A) 10 µL of DCM and 20uL of 
the aqueous sample are prefi lled in adjacent 384-wells. (B) Bi-layer system aft er pipetting 14µL of the aqueous phase 
(consisting of 71.5% methanol containing a green mix of crystal violet and fl uorescein and 14-fold diluted plasma) 
into the DCM. (C) Nitrogen Gas pressure assisted mixing of the phases. (D) Aft er 2 second aft er mixing the created 
emulsion is clearly observed in which the crystal violet has been extracted from the aqueous phase into the organic 
phase, while fl uorescein remains in the aqueous phase. (E) Bi-layer system aft er passive phase separation (typically 
around 90 seconds aft er the end of the mixing). (F) 2 µL is pipetted from the bottom of the DCM layer in order to be 
analysed by nanoESI-DI-MS. Th e precipitated proteins are visible in the aqueous phase. 
Eff ect of gas pressure and its duration on extraction
To study the mixing due to the gas fl ow, the eff ect of gas pressure and its duration on the ex-
traction effi  ciency during extraction was studied with four selected drugs as model analytes 
with varying size, pKa and log P (Supporting Table 1 and Figure 3). An equimolar mix of 
these drugs was spiked to human plasma (14-fold dilution in 71.5% methanol) at a concentra-
tion of 500 nM. Preliminary experiments using lower dilution factors resulted in less robust 
results (data not shown), probably due to the high protein content of human plasma.
To determine the extraction recovery, the steps aft er GPA-µLLE were modifi ed: 2 µL of the 
DCM phase was mixed with 2 µL of DCM containing 1 µM of the internal standards and 2 µL 
of this mix was infused for DI-MS analysis. By adding the internal standards only aft er the ex-
traction, we ensured that the internal standards could not be extracted into the aqueous phase 
during GPA-µLLE. As a consequence, we determined the relative recovery of the 4 drugs as 
the ratio of the intensity of drug and intensity of internal standard. Since methyl tert-butyl 
ether (MTBE) is a less toxic alternative to DCM[26], preliminary experiments with MTBE 
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instead of DCM were performed; however the infusion of MTBE extracts resulted in less 
stable nanoelectrospray currents (data not shown). Therefore, in all subsequent experiments 
DCM was used as an organic phase.
The gas flow through the tip was varied by choosing gas pressures of 0, 0.1, 0.3 and 0.5 psi for 
2, 10 and 20 seconds (Figure 3). A practical limitation of the applied gas pressure with the used 
volumes is the sputtering of liquid out of the well, which can cause contamination of other 
wells. In our system at pressures higher than 0.5 psi, small amounts of liquid were sputtering 
Figure 3 :  Average of the relative recovery (ratio of intensity of drug and its internal standard) versus the gas pressure 
and its duration of the 4 drugs. Internal standards are added only after the extraction, see text; n=3, error bars are 
expressed as the S.E.M.
out of the well. Therefore 0.5 psi was the maximum pressure used in order to obtain reprodu-
cible results. As expected, by applying no pressure (0.0 psi) the relative recovery of the drugs 
was minimal (as already shown in Figure 2B). The fact that at 0 psi already some extraction 
was observed was caused by dispensing the sample at the bottom of the DCM layer (Figure 
1B). From 0.3 psi upwards the recovery of the drugs did not seem to increase significantly, 
indicating that a higher gas flow at a higher pressure did not increase surface contact between 
both phases significantly any further.  The duration of the applied gas pressure had a positive 
effect on the extraction: a duration of 2 seconds resulted in the lowest recovery, whereas a du-
ration of 20 seconds provided the highest recovery. These results demonstrate that extraction 
of the drugs was improved significantly upon application of the gas pressure. Moreover, these 
results indicate that applying the gas pressure longer than 20 seconds would probably result in 
even higher recoveries. However, as there is a trade-off between speed and recovery we have 
chosen to minimize the time duration while still obtaining acceptable results.
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Performance evaluation  of GPA-µLLE
In the following experiments the analytical performance of GPA-µLLE was tested and com-
pared with conventional off-line LLE, and direct infusion of the aqueous sample (‘dilute and 
shoot’) after spinning down the precipitated proteins. For the comparison of these methods 
the same nanoESI and MS settings were used. Calibration curves were obtained by spiking the 
four model drugs to 14-fold diluted plasma at the 0, 25, 50, 100, 250, 500 and 1000 nM level 
with diltiazem and chlorpromazine as an internal standard (500 nM). Again, after spiking the 
drugs, the aqueous sample phase consisted of 71.5% methanol. Subsequently, the aqueous 
samples were subjected to analysis by GPA-µLLE -DI-MS, conventional off-line LLE/DI-MS 
and ‘dilute and shoot’ DI-MS after protein spin-down of the aqueous sample. In order to 
compare GPA-µLLE with conventional LLE, the same aqueous: DCM solvent ratio as in GPA-
µLLE was used, only the volumes were up-scaled in order to be able to perform the vortexing 
and centrifugation in 1.5 mL eppendorf tubes.  After 30 seconds of vortexing followed by 10 
minutes of centrifugation at 15 krcf, the DCM extract was carefully pipetted out of the tube 
and subsequently analyzed by DI-MS using the same settings as for GPA-µLLE. It should be 
mentioned that we also have tested a ‘dilute and shoot’ direct infusion of  the aqueous phase 
without precipitation of proteins; however, as expected, we could not obtain a stable spray 
probably due to clogging of the nanoESI emitter caused by abundant plasma proteins.
For the ‘dilute and shoot’ method the same aqueous sample phase (after protein precipitation) 
was analyzed whereas for both GPA-µLLE and conventional off-line LLE the DCM phase 
was analyzed as described above. From Table 1 it can be seen that for the drugs tested, our 
new GPA-µLLE method performed comparable or better than the conventional off-line LLE 
in terms of repeatability, linearity and limit of detection. Linear behavior was observed by 
measuring the normalized response of the analyte versus their concentration up to 2-orders 
of magnitude. The R2-values of the linear regression line of GPA-µLLE was good and ranged 
from 0.990 to 0.998 for the compounds tested. The precision of the GPA-µLLE measurements 
in plasma at 50 nM showed RSD values below 15%, except for lidocaine. This could be cau-
sed by a lower recovery due to lidocaine lowest log P and pKa, as extraction was carried out 
at neutral pH, (Supporting Table 1) and/or a lower ionization efficiency. The fact that the 
precision of our GPA-µLLE was improved over conventional LLE can be explained by the 
omission of the manual pipetting steps. The estimated LOD and LLOQ of GPA-µLLE seemed 
comparable with conventional, off-line LLE. The estimated LOD and LLOQ of loperamide 
were significantly higher than those of the other drugs. This is explained by the fact that a 
protonated ion with the same mass as loperamide was detected in the blank plasma, opposed 
to the other 3 drugs. In Figure 4, typical averaged mass spectra, zoomed in at the verapamil 

















lidocaine 43 21 0.992 0.990 5 9 17 30
propranolol 11 9 0.990 0.996 3 4 10 13
verapamil 26 9 0.993 0.995 2 3 7 10
loperamide 20 12 0.989 0.998 25 30 80 99
a concentration in 14-fold diluted plasma. b LOD was estimated by 3(SD25nM+ SDblank) / sloperesponse curve. 
c LLOQ was estimated by 3.3LOD.
Table 1: Analytical characteristics of GPA-µLLE of 14-fold diluted plasma compared  with conventional off-line LLE; 
n=5.
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m/z range from blank and spiked human plasma, aft er GPA-µLLE-nanoESI-DI-MS analysis 
are shown. It can be observed that for verapamil no protonated ion or carry over was detected 
in the blank plasma. Moreover, at the lowest dilution of 25 nM a protonated ion was clearly 
detected. It should be mentioned that the GPA-µLLE method did not require a centrifugation 
aft er mixing in order to facilitate phase settling as is required for conventional LLE methods. 
Th is was the advantage of the miniaturization of the whole LLE procedure, since only 2 µL 
of DCM had to be phase-separated for successful nanoESI-DI-MS analysis, which was well-
achieved within 90 seconds under our conditions.
Since we analyzed the aqueous phase with ‘dilute and shoot’ instead of the DCM in both LLE 
methods, we did not include these results in Table 1. However, with precision up to 62%, 
the ‘dilute and shoot’ method aft er protein precipitation performed signifi cantly worse than 
both LLE methods, as expected. Th is demonstrates that eff ective fractionation/pretreatment 
is important for the analysis of complex samples using DI-MS. Th ese fi ndings demonstrate 
the potential of GPA-µLLE as a rapid, fully-automated screening platform for small molecules 
in bioanalysis with excellent performance comparable with conventional off -line LLE. More-
over, as GPA-µLLE was integrated in a 384-well plate, it was compatible with handling small 
volumes in order of 2 µL with good precision. In principle, GPA-µLLE can be downscaled 
even more when smaller well-dimensions are used. Next to the analysis of the organic DCM 
phase aft er GPA-µLLE, the aqueous phase could in principle also be analyzed, depending on 
the application and the used solvents. However, due to high salt concentrations in a typical 
biological sample, ion suppression eff ects and potential clogging could occur when analyzing 
Figure 4: Typical averaged mass spectra zoomed in at verapamil (455-458 m/z) of blank and spiked human plasma 
analyzed with GPA-µLLE-nanoESI-DIMS. (A) In blank plasma, no protonated ion of verapamil was observed, while 
at (B) 25 nM concentration the protonated ion of verapamil as well as its isotopic ions can clearly be observed. As 
expected, at higher concentrations (C),(D) the intensities of the protonated and isotopic ions of verapamil is observed 
at higher levels.





the aqueous phase, especially when using DI-MS.
After mixing and settling of the phases, the precipitated plasma proteins were present in the 
aqueous phase (as observed in Figure 1F). During the last step of µ-LLE, in which 2 µL of the 
bottom DCM-phase is aspired for consecutive DI-MS analysis, the pipette tip punched throu-
gh the protein layer. Although this step could lead to protein contamination into the pipette 
tip, no indications of proteins in the DCM extract were observed: the resulting nanoESI spray 
was stable (around 10 nA) and moreover, in the 1000-2000 m/z range, no protein envelopes 
in the mass spectra could be observed.
Interestingly and also expected, many other plasma components were observed in the MS 
spectra and by tentative identification (based on exact mass), e.g. several plasma lipids were 
identified in the higher mass range (500-1000 m/z) (Figure 5), suggesting that GPA-µLLE 
might also be suitable for lipid profiling. On the other hand, these observations suggest that 
ion suppression effects could occur during the DCM analysis on the tested drugs. In future, 
by fine-tuning the solvents used for extraction, an optimized method could be developed in 
order to minimize ion suppression effects in terms of sensitivity. Moreover, the use of stable 
isotopically labeled internal standards is expected to improve precision. In order to further 
verify the suitability of our method for lipid analysis, we calculated the precision of 4 typical 
plasma lipids: LPC (18:3), LPC (20:5), PC (38:5) and PC (40:7) from the blank plasma repli-
cates with good RSD being 6, 9, 2 and 3%, respectively. Since no internal standard specifically 
for lipids was spiked, we normalized the 4 lipids with another endogenous abundant lipid, i.e. 
PC (36:5).
Since in GPA-µLLE the whole LLE procedure is automated, GPA-µLLE could be very suitable 
for rapid optimization of LLE procedures. Moreover, because in our method the samples are 
processed sequentially, the sample handling time is constant, making it also very suitable for 
extractive derivatization procedures. In this paper GPA-µLLE was integrated in an automated 
nanoESI-DI-MS robot and coupled online to MS. However, in the future GPA-µLLE could 
also be integrated into other platforms such as LC, CE and GC-MS, as long as the used auto-
Figure 5: Typical averaged mass spectrum of the 500-1000 m/z mass range of (blank) human plasma analyzed with 
GPA-µLLE-nanoESI-DIMS. Several lipids were putatively annotated based on exact mass.
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sampler/ sample preparation robot has the ability to apply a (controlled) gas flow through the 
liquid mixture. 
Application of GPA-µLLE to dried blood spot analysis
The developed GPA-µLLE was also applied to dried blood spots (DBS) samples because of the 
simplicity of the sample preparation procedure. A calibration experiment was carried out by 
spiking whole blood with lidocaine (0, 25, 50, 100, 250, 500, 1000 and 2500 nM) and spot-
ting these on a card and drying it for 7 days. In these experiments, the blood was not diluted.
Linear behavior was observed by measuring the normalized response of lidocaine versus its 
concentration over 3-orders of magnitude (Supporting Figure 1). The R2-value of 0.998 of the 
linear regression line of GPA-µLLE was excellent. The precision at 1000 nM was 9%, which 
is a favorable value to determine lidocaine in in a complex sample.  Actually, the therapeutic 
window of lidocaine in plasma is at an even higher concentration range,  i.e. between 6 to 25 
µM[27], proving the suitability of our method for clinical use. The aliquot of blood of the DBS 
punch was only 2.8 µL, resulting in a 7-fold dilution after adding the aqueous solvent. 
These results demonstrate that GPA-µLLE is also very promising for the rapid screening of 
drugs in DBS which could be useful in the pharmacokinetic screening in volume limited 
samples such as mouse plasma. However, it should be mentioned that the punching of the 
spot was performed manually and in an off-line manner. In future, further miniaturization of 
the punched spot size could be aimed for, which would enable more samples from one DBS, 
possibly for other analytical measurements, or  for backup samples.
CONCLUSIONS AND OUTLOOK
In this paper, we have presented a miniaturized and fully-automated LLE method for profi-
ling of small molecules based on gas flow mixing via a pipette through the solvent mixture 
followed by passive phase separation, coupled to nanoESI direct infusion mass spectrometry. 
We have shown that this method, which we called gas pressure assisted micro liquid-liquid 
extraction (GPA-µLLE), can be effectively used for the online clean-up of complex samples 
which was needed for reliable drug screening using nanoESI-DI-MS. The coupling of GPA-
µLLE to nanoESI-DI-MS  was  found  to  be suitable  for  the rapid extraction and analysis 
of spiked  drugs to  human  plasma  samples and importantly, resulted  in  a  stable  protein-
free nanoESI-MS signal. Moreover, compared to conventional LLE, GPA-µLLE showed an 
improved or comparable precision, linearity and sensitivity. Furthermore, the extraction can 
be optimized by varying the gas flow and its duration. Finally, the utility of the GPA-µLLE-
nanoESI-DI-MS was demonstrated for the analysis of lidocaine in DBS samples. In future, 
research could be directed towards further improvements of GPA-µLLE in terms of speed. By 
adding ultrasonic transducers below the well plate, extraction and phase settling times will 
probably be shortened. In addition, by using salting-out effect by addition of salt, the LLE pro-
cedure might also be faster and more efficient, only in case the organic phase is to be analyzed. 
Furthermore, GPA-µLLE is very suitable for performing rapid LLE optimization studies in 
which typical LLE parameters could be tested. Next to coupling to DI-MS, GPA-µLLE can 
also be integrated in other applications such as LC-MS, GC-MS. Moreover, in principle both 
aqueous as organic phase could be analyzed, depending on the application and solvents used. 
When large amount of samples needs to be processed, the well plate can be covered with a foil 
and/or the organic phase could be pipetted from a stock, in order to further control possible 
evaporation of solvents. Thanks to its combination of simplicity of the fully-automated setup 
and the ability to downscale LLE volumes, GPA-µLLE holds the promise to be integrated in 
many sample pretreatment modules for high-throughput screening in bioanalysis.
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with GPA-µLLE-DI-MS. A linear regression line is fitted through the average (n=4) of the normalized response; error 
bars are expressed as the S.E.M.
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Chapter 6
Testing tuberculosis drug effi cacy in a 
zebrafi sh high-throughput translational 
medicine screen
ABSTRACT
The translational value of zebrafi sh high throughput screens can be improved when more 
knowledge is available on uptake characteristics of potential drugs. We investigated reference 
antibiotics and 15 preclinical compounds in a translational zebrafi sh-rodent screening system 
for tuberculosis. As a major advance we have developed a new tool for testing drug uptake 
in the zebrafi sh model. This is important because despite the many applications of assessing 
drug effi cacy in zebrafi sh research, the current methods for measuring uptake using mass 
spectrometry do not take into account the possible adherence of drugs to the surface. Our 
approach combines nanoliter-sampling from the yolk using a micro-needle, followed by mass 
spectrometric analysis. As of to date no single physico-chemical property has been identifi ed 
to accurately predict compound uptake; our method offers a great possibility to monitor how 
any novel compound behaves within the system. We have correlated the uptake data with 
high-throughput drug screening data from M. marinum infected zebrafi sh larvae. As a result, 
we present an improved zebrafi sh larvae drug screening platform which offers new insights 
into drug effi cacy and identifi es potential false negatives and drugs that are effective in zebra-
fi sh and rodents. Thereby we demonstrate that this improved zebrafi sh drug screening plat-
form can complement conventional models of in vivo M. tuberculosis infected rodent assays. 
The detailed comparison of two vertebrate systems, fi sh and rodent, may give more predictive 
value for effi cacy of drugs in humans.
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INTRODUCTION
Studies in zebrafish larvae are increasingly used for modeling human diseases with the ex-
pectation that they will be able to contribute towards bridging the gap between in vitro cell 
based assays and in vivo mammalian disease models[1]–[3]. Zebrafish larvae have become a 
popular vertebrate model due to: i) their anatomical, molecular and genetic similarity to hu-
mans, ii) the availability of a large genetic toolbox, iii) their easy and low cost maintenance, iv) 
the optical transparency of embryos and larvae enabling massive phenotype-based screens, 
v) very few ethical issues associated with the use of larvae up to the feeding stage and vi) the 
occurrence of many pathological processes resembling various human diseases. Amongst nu-
merous other human diseases, tuberculosis (TB) has been modeled in zebrafish as a potential 
complement to the currently established in vitro and in vivo models proven to recapitulate 
the pathology of the human disease progression in zebrafish larvae[4]–[7]. In these systems 
efficacy of a drug can be accurately measured by its effect on the number of bacteria and their 
presence and survival inside immune cells[8]–[12]. As a result, zebrafish larvae have already 
yielded significant new insights into the understanding of the pathogenesis of TB in humans 
and contributed to the development of novel strategies for disease treatment[7]. Such a gain 
in understanding is very important since therapy of TB is becoming increasingly difficult with 
the emergence of new strains of bacteria resistant towards currently used antibiotic regimes 
(MDR, XDR, TDR)[13]–[17]. Although new drugs are being discovered the progress in FDA-
approval of anti-TB medicines is very limited[18]. Moreover, there is also a lack of effective 
vaccination against TB pending new approaches and strategies that are under evaluation for 
further improvement[13]. Therefore the need for more efficient novel drugs, targeting either 
the pathogen or the host, remains as high and urgent as ever[17], [19]. This task can only be 
accomplished by bringing together academic institutes and pharmaceutical companies with 
the aim of quickly implementing novel tools that have the potential of accelerating the drug 
discovery process. As an example of this strategy, GlaxoSmithKline (GSK) recently made pu-
blically available the structure and anti-TB properties of a set of 177 potent anti-tubercular 
compounds, making samples available to the industrial and academic research communities 
to stimulate early-stage TB drug discovery activities[20].
Given its previously mentioned attributes, zebrafish larvae can be potentially used at various 
stages of the drug discovery process, ranging from target identification and lead optimization 
to preclinical and clinical development[21]. The easy accessibility to large larvae numbers and 
their small size makes this model particularly suitable for high-throughput in vivo screening 
of drugs added to the medium[1], [2], [8], [22]–[24], significantly reducing material require-
ments for testing. However, caution must be taken when interpreting the data in the absence 
of knowledge on the way of absorption of drugs in the tissues of zebrafish larvae [25]. 
While the pharmaceutical industry is increasingly gaining confidence in the use of zebrafish 
larvae in a number of toxicity studies[21], [26]–[28], progress in the application of zebrafish 
as a possible alternative or complement to traditional in vitro and in vivo drug efficacy models 
has been limited[11], [29], [30]. Despite the previously mentioned benefits, a possible expla-
nation behind this lack of progress is the limited, or altogether missing understanding on the 
basic pharmacological parameters in zebrafish driving compound efficacy, namely uptake, 
distribution and metabolism[31].  
Mass spectrometry (MS) is an analytical technique which is very suitable for the quantifi-
cation and qualification of small molecules such as drugs and its metabolites. In the current 
state-of-the-art zebrafish assays, larvae are treated by adding the compound into their water 
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Here we demonstrate that the whole larvae lysis method is not always suitable for determi-
ning the uptake of drugs. This is due to the capacity of some molecules to persistently adhere 
to the skin, even after thorough washing, resulting in artificially high background readouts 
and false positive results for drug uptake. To palliate this, we present an alternative drug up-
take evaluation methodology in zebrafish larvae based on micro-needle sampling from the 
yolk followed by mass spectrometric analysis. Using this novel method two antituberculars in 
clinical use, rifampicin and moxifloxacin, and 15 preclinical lead compounds developed by 
GSK were examined. We correlate in vivo uptake levels with the efficacy of the compounds as 
measured in M. marinum and M. tuberculosis in vitro culture inhibition assays. Furthermore, 
the data obtained is also correlated with in vivo drug efficacy tests in a murine model of TB 
infection as well as with a high-throughput drug screening on M. marinum infected zebrafish 
(Figure 1). The results demonstrate the importance of standardized drug uptake studies in 
order to be able to understand and correlate the results obtained in zebrafish with other, com-
monly employed rodent efficacy models.
MATERIALS AND METHODS
Animal experiments ethic statement
All animal studies were ethically reviewed and carried out in accordance with European Di-
rective 2010/63/EU and the GSK Policy on the Care, Welfare and Treatment of Animals.
Zebrafish husbandry and compound treatment
Zebrafish of AB/TL wild-type strain were handled in compliance with the local animal wel-
fare regulations and maintained according to standard protocols (zfin.org). Embryos were 
collected from family crosses and grown at 28 °C in egg water (60 μg/mL Instant Ocean sea 
salts, Sera Marin) in dark.  At 3 day post-fertilization (dpf) 20-30 larvae were transferred 
to small, 35 x 10 mm Petri dishes each containing 3-4 mL of egg water supplemented with 
the following compounds: rifampicin (RIF; Sigma-Aldrich) and moxifloxacin (MOX; Santa 
Cruz) each at 150 µM, and GSK compounds (GlaxoSmithKline Pharmaceuticals) at 10 µM 
concentration. For controls dimethyl sulfoxide (DMSO) at 0,1% was used. Larvae were expo-
sed to the compounds for 17 and 40 hours. Controls were exposed for few seconds (T=0h). 
Compounds were administered separately to the larvae or in combinations. Compounds were 
refreshed every day. 
Assessing compound quantities in zebrafish larvae with lysis method
Larvae were transferred to 2 mL micro-centrifuge tubes one by one; excessive compound was 
removed, washed three times briefly with 1 mL 50 % methanol and then prepared for lysis. 
Lysis was performed based on snap freezing in liquid nitrogen followed by sonication, as 
previously described[39].
Micro-needle sampling from the yolk of zebrafish larvae
Before taking samples, larvae were transferred to 2 mL micro-centrifuge tubes, and then 
washed three times briefly with 1 mL 50 % methanol one by one. After washing, one larva was 
placed on 1% agarose plate and excessive methanol was removed. Under stereomicroscope at 
20 x magnification larvae were punctured in the yolk with a micro-needle (manually pulled 
borosilicate glass capillary, Harvard Apparatus) placed in the capillary holder of CellTram 
Oil micro-injector (Eppendorf) mounted onto a micro-manipulator workstation. Vacuum 
was generated manually via a rotating knob and the content of the yolk was extracted. When 
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the most of the content was removed from the yolk the suction was balanced and stopped. To 
recover the sample from the micro-needle into a micro-centrifuge tube a pressure was gene-
rated by turning the knob in the opposite direction.
Determination of the sample volume 
Since individual larva can differ in their yolk size and volume; and the manually pulled micro-
needles used for sampling were not identical in diameter, the sampled volume was not always 
the same per larva. In order to quantify the drugs in the sample, the volume has to be known. 
As a consequence, images of every sample were taken including the micro-needle containing 
Figure 1: Scheme of drug efficacy methods: antibacterial activity and uptake assays in the zebrafish model integrated 
in conventional disease screening pipeline. Different models are used in our workflow to determine the efficacy of an-
titubercular compounds (from left to right): (a) Initially, the in vitro efficacy of the tested compounds are determined 
by their minimum inhibitory concentration (MIC) against Mycobacterium marinum and Mycobacterium tuberculosis 
cultures using fluorimetric and colorimetric read-outs from resazurin assay. Subsequently, biological validation is 
performed in in vivo models (b-d). (b) First, compound efficacy is screened in M. marinum infected zebrafish larvae. 
Embryos are robotically injected and following compound treatment the percentage of inhibition is determined 
using fluorescence read-out of COPAS system. (c) To unravel whether certain compounds fail to be active in zebra-
fish larvae due to lack of antibacterial activity or poor uptake, our micro-needle sampling method combined with 
mass spectrometry is used to assess uptake levels from samples of the yolk. (d) As gold standard in antitubercular 
drug development, compound efficacy is established by determining the rate of the colony forming units (CFU) 
reduction in the lungs of M. tuberculosis infected rodents. After setting (arbitrary) cut-offs in all models, compounds 
could be categorized into positive or negative groups. By the comparison of these groups along the pipeline, our 
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the sample. The volume of the samples was determined by modeling the needle as a cone 
and measuring the diameter and the length on the image, using the scale bar as a reference. 
Since the angle for the capillary holder was always adjusted in a 45° angle we also adjusted the 
model for this projection. This way the results were normalized with the according sample 
volume. Sample volumes were typically around 50 nL, varying between 20 - 200 nL.
Sample preparation
After recovering the sample from the micro-needle into the micro-centrifuge tube, 75% me-
thanol including internal standards (IS) were added to the sample (rifabutin and levofloxa-
cin as a IS for rifampicin and moxifloxacin respectively, and ampicillin as an IS for the GSK 
compounds). For the micro-needle samples an IS concentration of 20 nM was used. For the 
whole larvae samples the spiked IS resulted in a concentration of 250 nM. After vortexing for 
2 minutes the precipitated proteins were spun down by centrifuging at 16.1 krcf for 5 minutes 
at 0°C. The supernatant was used for LC-MS analysis.
Mass Spectrometry
A Surveyor Plus UPLC system was used and 15 µL sample was injected on a Acquity C18 T3 
column (2.1x100 mm, 1.8 µm). Mobile phase A was 99% H2O and 1% acetonitrile with 0.3% 
formic acid. Mobile phase B was 90% acetonitrile and 10% H2O with 0.3% formic acid and 
the flow rate was 500 µL/min. A LTQ Orbitrap XL (Thermo Fisher Scientific) was used for 
detection of the ions in positive electrospray mode. The electrospray voltage was 4.5 kV. The 
capillary temperature was 375°C and the capillary and tube lens voltage was 29 V and 120 V, 
respectively. The sheath gas flow rate and aux gas flow rate was 35 and 10 units, respectively. 
Resolution was set to 7500 in order to reduce the scan time and thus increase the number of 
data points. For the quantification of the samples an academic calibration curve was construc-
ted within every batch.
M. marinum infections in zebrafish in vivo model
Infection experiments were performed on zebrafish embryos at early developmental stages 
(up to 1,024-cell stage) injected with 40 CFU Mycobacterium marinum M strain into the yolk 
using automated robotic injection system as described in Carvalho et al.[8]. As a control an 
equal volume of carrier solution was injected. After injection, embryos were incubated at 
280°C in egg water in Petri dish. Starting at 3 days post-fertilization (dpf) 200 larvae were 
treated with the following compounds till 5 dpf by adding the compounds into egg water: 200 
µM rifampicin (Sigma-Aldrich), 10 µM GSK compounds and dimethyl sulfoxide (DMSO) 
(0,1%) as negative control. Water with compounds was refreshed once daily. Bacterial in-
fection was quantified using Complex Object Parametric Analyzer and Sorter (COPAS) XL 
(Union Biometrica) as described previously[8]. Fluorescence in the posterior half of the lar-
vae was determined using a custom perl script that analyses the COPAS extinction profile to 
determine the posterior half and then sums the fluorescent values of all data points for that 
half.
M. tuberculosis H37Rv inhibition assay 
The measurement of the minimum inhibitory concentration (MIC) was performed as des-
cribed in Ballell et al.[20]. For each compounds measurements were performed in 96-well 
flat-bottom polystyrene micro-titer plates. Ten twofold drug dilutions in neat DMSO starting 
at 50 mM were performed. These drug solutions (5 µL) were added to 95 µL Middlebrook 
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7H9 medium (lines A–H, rows 1–10 of the plate layout). Isoniazid was used as a positive 
control; eight two-fold dilutions of isoniazid starting at 160 µg/mL were prepared, and this 
control curve (5 µL) was added to 95 µl Middlebrook 7H9 medium (row 11, lines A–H). Neat 
DMSO (5 µL) was added to row 12 (growth and blank controls). The inoculums was standar-
dized to ~1x107 CFU/mL and diluted 1:100 in Middlebrook 7H9 broth (Middlebrook ADC 
enrichment, a dehydrated culture medium which supports growth of mycobacterial species, 
available from Becton–Dickinson, cat.# 211887), to produce the final inoculum of H37Rv 
strain (ATCC25618). This inoculum (100 µL) was added to the entire plate except G-12 and 
H-12 wells (blank controls). All plates were placed in a sealed box to prevent drying out of the 
peripheral wells and were incubated at 370°C without shaking for six days. A resazurin solu-
tion was prepared by dissolving one tablet of resazurin (VWR International Ltd., Resazurin 
Tablets for Milk Testing, cat.# 330884Y’) in 30 mL sterile phosphate-buffered saline (PBS). Of 
this solution, 25 mL were added to each well. Fluorescence was measured (Spectramax M5, 
Molecular Devices; λex=530 nm, λem=590 nm) after 48 h to determine the MIC value.
M. marinum inhibition assays
The measurement of the minimum inhibitory concentration (MIC) was performed as descri-
bed above in for the M. tuberculosis H37Rv inhibition assay with minor changes. Each com-
pound measurement was performed in 96-well flat-bottom polystyrene microtiter plates. Ten 
two-fold drug dilutions in neat DMSO starting at 50 µM were performed. These drug soluti-
ons (2 µL) were added to 98 µL Middlebrook 7H9 medium (lines A–H, rows 1–10 of the plate 
layout). Isoniazid was used as a positive control; eight two-fold dilutions of isoniazid starting 
at 100 µM were prepared, and this control curve (2 µL) was added to 98 µL Middlebrook 7H9 
medium (row 11, lines A–H). Neat DMSO (2 µL) was added to row 12 (growth and blank 
controls). The inoculum was standardized to ~2x105 CFU/mL and diluted 1:1 in Middlebrook 
7H9 broth (Middlebrook ADC enrichment, a dehydrated culture medium which supports 
growth of mycobacterial species, available from Becton–Dickinson, cat.# 211887), to produce 
the final inoculum. This inoculum (100 µL) was added to the entire plate except C-12 and 
D-12 wells (blank controls). All plates were placed in a sealed box to prevent drying out of 
the peripheral wells and were incubated at 280°C without shaking for three days. A resazurin 
solution was prepared by dissolving one tablet of resazurin (VWR International Ltd., Resazu-
rin Tablets for Milk Testing, cat.# 330884Y’) in 30 mL sterile phosphate-buffered saline (PBS). 
Of this solution, 25 µL were added to each well. Fluorescence was measured (Tecan infinite 
200Pro; λex=535 nm, λem=590 nm) after 48 h to determine the MIC value.
M. tuberculosis infections in mouse in vivo model
Infections of mice with Mycobacterium tuberculosis was initiated by nonsurgical intratracheal 
instillation of M. tuberculosis H37Rv as previous described by Rullas et al.[29]. In brief, 8- to 
10-week-old female mice were anesthetized with 3% isoflurane and intubated with a metal 
probe (catalog number 27134; Unimed SA, Lausanne, Switzerland). The inoculum (105 CFU/
mouse suspended in 50 µL of phosphate-buffered saline) was put into the probe and delivered 
through forced inhalation with a syringe. Treatment was started 24 hours after infection, to 
allow for phagocytosis of instilled bacteria, and lasted up to 7 days post infection. Finally, an 
additional 24 h was allowed for clearance of compounds before organ harvesting. To measure 
infection burden in lungs, all lobes were aseptically removed and homogenized. The homo-
genates were supplemented with 5% glycerol and stored frozen (-80 °C) until plating. After 
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percount; Synoptics Ltd., Cambridge, United Kingdom) and confirmed by visual inspection 
to correct potential misreadings. Bacterial growth of about 2 logs over the initial inoculum 
was determined to be a level that would provide enough dynamic range to detect statistically 
significant growth inhibition. 
Statistical Analysis
COPAS data were analysed (Prism 4.0, GraphPad Software) using nonparametric, two-tailed 
Wilcoxon signed-rank test, and the uptake data were analysed using  unpaired, two-tailed t-
test. P values shown are: *P<0.05, **P<0.01, and ***P<0.001.
RESULTS
Assessing rifampicin and moxifloxacin quantities in zebrafish by lysis of whole larvae 
We have recently reported an automated high-throughput drug screening protocol using My-
cobacterium marinum infected zebrafish larvae[8]. To better understand the efficacy of anti-
tuberculosis compounds used in this test system, we performed uptake experiments using 
mass spectrometry. This improved zebrafish drug screening platform could then be integrated 
into the conventional disease screening pipeline and give more predictive value for human 
efficacy of antitubercular compounds (Figure 1). 
To assess the quantity of drugs present in zebrafish, larvae were exposed to rifampicin, a first-
line anti-TB drug used as a positive control in our drug screening experiments[8], [22], as 
well as to moxifloxacin, a gyrase inhibitor currently under exploration for novel antitubercu-
lar regime development to shorten the duration of TB treatment[34]. 
First we measured the quantities of the aforementioned compounds using the previously des-
cribed whole larvae lysis method followed by LC-MS analysis[28]. After different exposure 
times (17 and 40 hours) larvae were washed with 50% methanol and lysed individually to 
determine drug concentration using LC-MS (Figure 2a). A steady increase was detectable in 
the level of moxifloxacin during the treatment period from 3.1 pmol/larva at 17 hours of ex-
posure and increasing further to 13.6 pmol/larva at 40 hours of exposure. On the other hand, 
rifampicin seemed to have reached a steady state level already at 17 hours of exposure with 6.2 
pmol/larva and 6.6 pmol/larva at the 40 hour exposure time. As a control we quickly expo-
sed the larvae to the drugs for only a few seconds, then washed them immediately with 50% 
methanol and lysed them for analysis (T=0 h). Surprisingly, the presence of both drugs was 
detected even after these few seconds of exposure, at which time rifampicin was measured at 
4.6 pmol/larva and moxifloxacin at 0.8 pmol/larva. Washing after drug exposure was also per-
formed using other solvents (embryo medium, 5% and 50% ethanol), which resulted in the 
same quantitities as were detected after 50% methanol wash (data not shown). Detection of 
rifampicin and moxifloxacin in the T=0 h control lysates was presumably due to the tendency 
of these drugs to adhere to the skin of the larvae. These results suggest that the whole larvae 
lysis method is not suitable for monitoring drug uptake.
Determining uptake of rifampicin and moxifloxacin using micro-needle sampling 
Since the larvae lysis method cannot be used for correctly monitoring the uptake of certain 
drugs, we aimed to overcome this issue by taking samples (in the nanoliter range) from the 
yolk of zebrafish larvae using a micro-needle attached to an Eppendorf CellTram Oil. As 
detailed in the material and methods section we also have developed a method to accura-
tely determine the sample volume needed for quantitative mass spectrometric analysis.  This 
method was used to analyze samples in the same time-course experiment as applied in the 
lysis method (17 and 40 hours of exposure). We observed a gradual increase in the uptake 
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level of both rifampicin (17 hours of exposure at 1.1 µM, 40 hours of exposure at 9.2 µM) and 
moxifloxacin (17 hours of exposure at 8.7 µM, 40 hours of exposure at 41 µM) (Figure 2b). 
Neither rifampicin nor moxifloxacin was detected at the control time point (T=0 h), indica-
ting that our new method eliminates the issue of drug adherence. The results show that our 
method can measure drug uptake with high accuracy and sensitivity from samples in the na-
noliter range and is also suitable for compounds that persistently stick to the surface of larvae 
such as rifampicin.in the nanoliter range and is also suitable for compounds that persistently 
stick to the surface of larvae such as rifampicin.
Uptake of preclinical anti-tuberculosis compounds and correlation with their efficacy on 
bacterial burden in infected zebrafish larvae 
In order to correlate the uptake of a drug with its in vivo effect on microbial infection using 
drugs that were not previously tested in our zebrafish model, we performed an anti-TB drug 
screening on M. marinum infected zebrafish larvae using 15 preclinical compounds provided 
by GSK.  These compounds were pre-screened in vitro for their antibacterial activity on M. 
tuberculosis and M. marinum cultures showing a large gradient of activities (Supporting Table 
1). For the in vivo test, zebrafish embryos were robotically injected with fluorescently labeled 
bacteria at early stages of development and hatched larvae were treated with compounds from 
3 days post-infection (dpi) following the protocol as published by Carvalho et al.[8]. The an-
tibacterial efficacy of the compounds was assessed by monitoring the fluorescence intensity 
correlating with bacterial burden present either in the total body or only in the tail region of 
5 day-old zebrafish larvae using COPAS analysis. The efficacy was expressed as percentage of 
inhibition relative to DMSO treated control groups (Figure 3). The tail region is representa-
tive of a part of the body where mycobacteria are mainly enclosed by immune cells leading 
to granulomas and therefore presents a good measure for disseminated disease[8], [35]. The 
tail measurements compared to the total body are an indicator for potential problems with 
drug distribution. Compared to the control we identified compounds reducing bacterial load 
significantly and others that had moderate or no significant effect on infection (Figure 3). The 
results show that at least 3 compounds were significantly active on reducing bacterial burden 
both in the total body and the tail region. In order to better understand the reason for a com-
Figure 2: Rifampicin and moxifloxacin quantities measured by (a) whole zebrafish larvae lysis method and (b) mi-
cro-needle sampling method from the yolk. Three day-old zebrafish larvae were exposed to the combination of 
rifampicin (RIF; grey bars) and moxifloxacin (MOX; white bars) dosed at a 150 µM concentration for 0, 17 and 40 
hours (n = 10). Note that as a control at 0 time point (T=0 h) the zebrafish larvae were exposed to the compounds (at 
the same dose) for only few seconds. This short exposure was followed by three consecutive washing steps with 50% 
methanol. In the read-out, (a) after lysis of the whole larvae the presence of compounds is detected even at T=0 h, 
however (b) via our micro-needle method the compounds are undetectable in the yolk at T=0h. All data are expres-
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pound failing to lower bacterial load in the zebrafish, we determined GSK compound levels 
in samples taken from yolk of larvae at 5 dpf after 40 hours treatment (Figure 3a). The compa-
rison revealed a correlation between the uptake and the antibacterial efficacy of compounds 
both in the total body and the tail region (Figure 3a, b, c).
Figure 3: Correlation between the uptake level of preclinical antitubercular compounds and their efficacy in M. ma-
rinum zebrafish infection model. (a) Uptake levels of 15 preclinical antitubercular GSK compounds were measured 
from samples taken from the yolk of 5 day old zebrafish larvae after 40 hours exposure at 10 µM concentration (black 
bars) (n=10). Efficacy of the compounds was assessed by monitoring fluorescent bacterial burden in the total body 
(red bars) or tail region (orange bars) of 5 dpi larvae using the COPAS system after 40 hours treatment (n=200). Ef-
ficacy is expressed as percentage of inhibition relative to DMSO treated control groups. The bar graphs depict the 
correlation between the uptake and the relative inhibition, both in the total body and the tail region. Significance in 
inhibition is indicated with asterisks (***P<0.001). (b, c) Correlation between the efficacy (b) in the total body or (c) 
in the tail and the uptake of the GSK compounds.
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Correlation between drug uptake levels and physico-chemical properties
It is important to determine if the uptake level of a compound can be correlated with its 
physico-chemical properties; if such a relationship was identified it would allow effective 
prediction of the uptake of compounds in this model. We compared a number of common 
metrics used in predictive strategies to the uptake levels measured in our assays. In our case 
no relationship was found for the majority of the metrics examined (molecular weight, mo-
lecular volume, number of rotatable bonds, hydrogen bond acceptors/donors, number of sp3 
carbons, number of aromatic rings, number of Lipinski H-bond acceptors/donors, and polar 
surface area; see Supporting Figure 2). One metric did show a weak relationship with the 
measured uptake, chromlogD – which represents the lipophilicity of a compound (Figure 
4). This, experimentally determined property, is the chromatographic hydrophobicity index 
(CHI)[36], a retention time of the compound at pH 7.4 on a fast gradient reverse phase HPLC 
column, modified by a conversion factor which has been shown to be more accurate than 
classical OW partitioning[37]. Only a weak correlation was identified between high chrom-
logD (above 3.5) and uptake. This is in line with other findings and confirms that it is hard 
to accurately predict uptake of compounds solely based on their physico-chemical properties 
such as lipophilicity[21], [31]. Our micro-needle sampling method gives valuable additional 
information on transportability of particular drugs through epithelial layers and could lead to 
better theoretical models for use in combination with physico-chemical predictions.
Figure 4: Correlation between uptake levels and compound hydrophobicity. ChromlogD is the representation of 
the hydrophobicity and therefore the solubility/ lipophilicity of a compound. To examine the relationship between 
ChromlogD of the compounds and their uptake ChromlogD is plotted against uptake levels measured in 5 day old 
zebrafish larvae after 40 hours exposure. A weak correlation is observed between high chromlogD (above 3.5) and 
uptake.
Comparison of uptake levels with in vitro and in vivo antibacterial efficacy models used in 
our pipeline of anti-TB drug discovery
We aimed to elucidate if the uptake and antibacterial efficacy results obtained from the ze-
brafish model translate to other models commonly used in the drug development pipeline. 
For this reason, we first compared zebrafish data to in vitro M. marinum antibacterial efficacy 
models. 
To determine if there is correlation between uptake and the antibacterial activities, first we 
normalized the data for the uptake with the minimum inhibitory concentration (MIC) of 
compounds against M. marinum (Figure 5). This Log(uptake/MIC) ratio identifies which 
compounds are present in the larvae at concentrations in excess of their MIC values. Using 
this data a plot of the Log(uptake/MIC) against the observed percentage of inhibition in the 
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the Log(uptake/MIC) was below zero significantly reduced the bacterial burden in the entire 
body in zebrafish (GSK12, GSK13, GSK19). However, from the 12 compounds, which were 
present in concentrations well above their MIC values, only 4 were active (indicated with 
green) (GSK 10, GSK14, GSK37, GSK43). 
Furthermore, we extended our comparison with in vitro M. tuberculosis antibacterial efficacy 
data as well as with in vivo M. tuberculosis infected mouse efficacy data, the latter being a 
gold standard in anti-tuberculosis drug development (Figure1). In the acute mouse model the 
inactive compounds are defined as compounds that produced less than a 2 log reduction in 
CFU count[29] (Supporting Table 2). Conversely, active compounds are those that produced 
a greater than 2 log reduction in the CFU count in the acute mouse model. Of the 4 active 
compounds identified via the zebrafish screening only 2 (GSK14, GSK37) are considered as 
active in mouse experiments, whereas the other 2 compounds (GSK10, GSK43) were inactive 
in the mouse model. Of the 11 compounds detected as inactive in zebrafish assay 6 proved to 
be inactive in mouse as well (GSK6, GSK12, GSK13, GSK30, GSK34, GSK38) showing that 
both in vivo models yield very different results from the in vitro MIC data.
Figure 5: Correlation between uptake and in vitro minimum inhibitory concentration and in vivo zebrafish antibac-
terial activities of compounds. The measured uptake data in zebrafish larvae is normalized with in vitro minimum 
inhibitory concentration (MIC) of compounds against M. marinum (Log(uptake/MIC)). This ratio is plotted against 
the observed percentage of inhibition in the zebrafish M. marinum infection assay. Size of the circles indicates their 
MIC values. Green colour represents compounds significantly reducing bacterial burden in zebrafish infection mo-
del, considered as active compounds, while red colour indicates inactive compounds.
DISCUSSION
Zebrafish larval screening systems have increasingly been used for testing the effects of drugs. 
Especially, in the context of drug screening against tuberculosis, current methodologies based 
on bacterial load reduction are accurate and can be automated. In the case of antibiotic screens 
this has led to valuable information on the efficacy of existing and new antibiotics using M. 
marinum infection as a test system[8], [11], [12], [38]. However, the reasons behind the fai-
lure of some compounds to lower bacterial load in M. marinum infected zebrafish larvae were 
unclear and we wanted to test whether this was caused by poor compound uptake. To date, 
the mass spectrometric methods currently in use fail to correctly monitor uptake levels in 
zebrafish. In order to address this problem, we decided to explore an alternative methodology 
that could measure uptake of compounds from the yolk of zebrafish larvae by micro-needle 
sampling followed by mass spectrometric analysis. The results show that micro-needle sam-
pling of volumes in the nanoliter range from the yolk allows accurate and sensitive analysis of 
uptake of drugs by individual larvae.
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Our method is based on the assumption that taking samples from the yolk is relevant for 
predicting limitations of drug efficacy in the rest of the body of zebrafish larvae. This assump-
tion is supported by measured quantities in the yolk and whole larvae lysis experiments for 
moxifloxacin (Supporting Figure 1). We have compared antimicrobial efficacy in the entire 
body with the tail region in order to check whether spreading of the tested drugs through the 
body could present a problem (Figure 3). These results do not show any indication that the 
effect of the 15 tested compounds is limited by distribution through the body and therefore 
indicate that the yolk is a representative location for measuring drug uptake. 
Our results show that there is a high variety of uptake of the various tested compounds. As 
expected, only compounds that reach uptake levels that are greater than their MIC are ac-
tive in our antimicrobial test system. In some cases uptake shows to be a limiting factor for 
reaching the MIC as determined in vitro (Figure 5). The fact that this outcome could not be 
predicted solely based on physico-chemical properties like hydrophobicity or mass shows the 
importance of our test system. At least in one case (compound GSK19) it is clear that the dif-
ference with the effect in the rodent test system can be explained by problems with uptake by 
the zebrafish larva (Figure 1). By explaining false negative test results from large screens, our 
microsampling method opens new possibilities for drug screening using zebrafish larvae in 
a preclinical test set up. In the future our screening pipeline can also be the basis for in depth 
studies of the mechanisms behind this and other false negative test results in zebrafish. It is 
also interesting to study why some drugs that did show high efficacy in the zebrafish larvae 
model were inactive in the mouse model.  This could be examined for instance by testing 
other drug administration methods, e.g. drugs can be injected directly inside the body or 
added to the food instead of the medium. This can show whether the negative results in the 
rodent test model are caused by degradation of drugs added to the food in the acidic environ-
ment of the stomach. 
In addition to highlighting the importance of identifying potential false negative and positive 
test results, our results show that some drugs that come out as most positive in the combined 
uptake and efficacy zebrafish test system are also active in the in vivo rodent model. This is 
of significance since zebrafish larvae do represent a very different test system as compared 
to rodents for instance with respect to (1) method of application (in the medium versus ap-
plication in the food in the rodent system), (2) metabolic rate of these test system (where 
zebrafish present a metabolic rate that is much slower than rodents), and (3) different levels of 
genetic polymorphisms (the zebrafish strains are wild types with very high number of poly-
morphisms whereas the mouse strains are highly inbred and devoid of polymorphisms). We 
therefore believe that the zebrafish model provides added value to the rodent system since, in 
comparisons with the human population, test models with a larger number of polymorphisms 
and a lower metabolic rate are of relevance. In a broader perspective the observation that 
compounds that are active in two highly different test systems (in this case a fish versus a ro-
dent) could provide additional confidence that the compound will also provide high efficacy 
in human subjects with varying background genotypes. Some of the compounds tested in this 
study (such as GSK14, which was shown to have good uptake and high efficacy in the zebra-
fish system) are members of series of compounds which are currently progressing to extensive 
medicinal chemistry programs that hopefully lead to clinical applications in the near future.
We therefore anticipate that the novel uptake measurement technique presented here makes 
important inroads to our understanding of zebrafish infection model data and opens up new 
opportunities for zebrafish larval systems to be more widely employed in the field of phar-
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testing in zebrafish larvae testing and in this case it will also be of great added value to rodent 
toxicity test systems. We hope that our results will stimulate future detailed follow-up phar-
macokinetic studies in this model system. In conclusion, our results are a good starting point 
to undertake more detailed PK/PD studies together with studies of reference compounds that 
eventually can lead to full acceptance of the zebrafish as a model in pharmacological scree-
ning pipelines in industry.
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SUPPORTING INFORMATION
Supporting Figure 1: Comparison of the amount of moxifloxacin measured in the samples from the yolk and lysates 
of whole zebrafish larvae. Level of moxifloxacin was measured  after 17 (4 day old larvae) and 40 hours (5 day old 
larvae) of drug exposure using samples from the yolk (white bars) and from the lysates of whole larvae (grey bars) 
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Supporting Figure 2: Uptake versus physico-chemical properties. Common metrics used in predictive strategies was 
compared to the uptake levels of the 15 compounds used in our assays. In the examination uptake level was compared 
to (a) molecular weight, (b) molecular volume, (c) number of rotatable bonds, (d) hydrogen bond acceptors and (e) 
donors, (f) number of sp3 carbons, (g) number of aromatic rings, (h) number of Lipinski H-bond acceptors and (i) 
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Compound  MIC M.tuberculosis (µM)  MIC M.marinum (µM)
GSK6    0,08    1,56
GSK10    0,06    0,39
GSK11    1,11    6,25
GSK12    1,59    6,25
GSK13    0,9    6,25
GSK14    0,47    0,39
GSK17    0,03    0,78
GSK19    0,12    0,78
GSK20    0,04    0,39
GSK30    0,06    0,78
GSK32    0,04    0,39
GSK34    0,08    0,78  
GSK37    0,22    12,5
GSK38    0,04    0,78
GSK43    1,28    6,25
Supporting Table 1: Minimum inhibitory concentration of compounds
Compound  CFU reduction
GSK6    1,65
GSK10    0,1
GSK11    2,85
GSK12    1,76
GSK13    0,03
GSK14    2,92
GSK17    2,98
GSK19    2,52
GSK20    4,65
GSK30    1,95
GSK32    3,7
GSK34    0,99
GSK37    2,3
GSK38    1,14
GSK43    1,06
Supporting Table 2: Log reduction in CFU count in the acute mouse model
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CONCLUSIONS AND PERSPECTIVES
With the persistent efforts to improve healthcare while the costs are ever-increasing, there 
is a growing demand for healthcare innovations including faster and cheaper analytical me-
thods to support clinical decisions. The in-depth phenotyping of a biological system, such as 
comprehensive small-molecule profiling, will be key for breakthroughs in biomedical and 
pharmacological research towards the development of personalized medicine. However, there 
is often an inverse relation between sensitivity (coverage of the number and type of small-
molecules) and the speed and costs of the assay. Although classical small-molecule assays 
such as microscopy- and enzyme-linked immunosorbent assays predominantly rely on single 
analyte readouts at a possible high-throughput manner, there is a need for more in-depth 
small-molecule assays while maintaining reasonable throughput. Yet the comprehensive, 
high-throughput profiling of a wide variety of small molecules is a major challenge, especially 
in the field of metabolomics.
In this thesis the development of new methods towards high-throughput, mass spectrometry-
based profiling of small molecules in complex biological samples is presented. One option 
for high-throughput mass spectrometric profiling is direct infusion in which no separation 
techniques are employed prior to MS detection. With the pre-analytical part being a major 
bottleneck in a typical direct-infusion MS-based analytical workflow, the focus was set on the 
development of new sample pretreatment and sampling procedures, including miniaturized 
and automated concepts with the potential for high-throughput application.
In Chapter 2 the current state-of-the-art in sample pretreatment techniques for mass spec-
trometry-based metabolomics has been reviewed. Although to date no universal sample pre-
treatment technique is available for the comprehensive analysis of the metabolome, the com-
bination of protein and lipid removal is often reported to be an effective strategy to improve 
metabolite coverage and reproducibility. It has been described that the recent innovations in 
automated offline well-plate extraction (including  protein precipitation (PPT), liquid-liquid 
extraction (LLE) and solid-phase extraction (SPE) have allowed fast sample cleanup and part-
ly removed the bottlenecks associated with sample pretreatment. It has been suggested that 
in the future sample pretreatment procedures should not only be automated and fast, but also 
quantitative and standardized so that metabolomics data of different studies are comparable 
within and between labs. This is especially important as some metabolites can be partly bound 
to proteins or other factors in blood, and are partly free in solution.
In Chapter 3 the rapid phenotyping of early zebrafish embryogenesis using nanoESI high 
resolution (HR) direct infusion mass spectrometry (DI-MS) has been described. It has been 
demonstrated that with limited but efficient sample pretreatment in-depth profiles could be 
obtained which could distinguish five developmental stages of early embryogenesis with a 
time resolution of 1 hour. It has been shown that with thorough data cleanup, 102 molecular 
features proved relevant which reflected the onset of (earlier reported) gene expression and 
the increase in energy requirement. It was concluded that effective and preferably fast sam-
ple pretreatment procedures are desirable to obtain more reproducible in-depth information 
about metabolites at lower concentrations. 
By using limited sample preparation and proper data processing, in-depth metabolic profiles 
of complex samples can be obtained using nanoESI-DI-MS. Still, in order to exploit the full 
potential of DI-MS, effective sample pretreatment/fractionation methods should be develo-
ped (as proposed in Chapter 4 and 5) which preferably includes the extraction of small polar 
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In Chapter 4, three-phase electroextraction (3-phase EE) into a two microliter droplet, which 
was hanging from a conductive pipette tip, has been described. By the electromigration of 
analytes from a larger volume of aqueous sample, through an immiscible organic filter phase, 
into a small-volume of aqueous acceptor phase, a fast analyte enrichment of metabolites has 
been achieved. The organic filter phase composition imposed the selectivity of 3-phase EE, a 
feature which is useful in tuning the extraction into the analyte window of interest, and thus 
preventing the migration of proteins into the acceptor phase. Therefore, 3-phase EE has great 
versatility as analyte enrichment and purification (deproteinization) can be integrated in one 
single method. Proof of principle towards the online integration in an automated nanoESI-
DI-MS platform has been realized which shows the potential of 3-phase EE in HTS. 
It is expected that the range of analytes compatible with 3-phase EE may be extended by the 
optimization of the organic filter phase composition which may make 3-phase more suitable 
for comprehensive profiling purposes. In addition, though not demonstrated in this thesis, 
3-phase EE might have desalting properties caused by the organic filter phase. Furthermore, 
by the optimization of 3-phase EE geometries, enrichment could be further improved. In 
future, by using microfluidic-chip technologies, 3-phase EE could be further downscaled and 
the potential of massive parallelization in the context of high-throughput screening (HTS) 
could be explored.
In Chapter 5 a miniaturized automated LLE has been developed in a 384 well-plate based 
on gas pressure-assisted mixing followed by passive phase separation. Our method enabled 
the whole extraction procedure being executed and integrated in an automated nanoESI-DI-
MS robot. Through varying the gas pressure and its duration, the effectiveness of the mixing 
procedure in terms of recovery has been optimized. It has been demonstrated that for drugs 
in human plasma, this new platform proved excellent analytical characteristics in terms of 
precision and linearity compared to e.g. a conventional LLE procedure. These experiments 
show the potential of this new fully-automated platform for the analysis of drugs in complex 
(volume-limited) samples such as plasma and dried blood spots. 
As demonstrated in this thesis, the dichloromethane phase can be successfully analyzed after 
the LLE procedure, which makes this method very suitable for the analysis of relatively apo-
lar, small molecules such as drugs but possibly also lipids. In principle, both phases could be 
infused as the analysis of the (cleaned-up) aqueous phase might also be useful for measuring 
the more polar molecules. However, caution must be exercised when the aqueous phase con-
tains high salt concentrations and dilution might be an extra step which should be taken into 
account.
In Chapter 6 a miniaturized sampling method using a microneedle has been described which 
enabled monitoring drug uptake in the (small-volume) yolk of zebrafish larvae using MS 
analysis. It has been demonstrated that the current methods based on embryo lysis did not 
take into account the possible adherence of drugs to the skin, resulting in false-positive up-
take readouts. It has been shown that our new method offers a great possibility to monitor 
how any novel compound behaves within the zebrafish system, as to date no single physico-
chemical property has been identified to accurately predict compound uptake. With our new 
method, the uptake data of two commonly used anti-tuberculars, together with 15 preclinical 
compounds, have been monitored and correlated to high-throughput screening data from M. 
marinum infected zebrafish larvae as well as to other conventional in vivo and in vitro models. 
It has been proposed that our improved zebrafish drug screening platform could obtain new 
insights into interpretation and prediction of drug efficacy. 
It is expected that this method opens a doors for the use of zebrafish embryos for in-depth 
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pharmacological assessment of activity (such as PK modelling) and therefore enables a wider 
acceptance for the zebrafish in the field of drug discovery and development. Moreover, next 
to the targeted drug analysis, a comprehensive profiling of small molecules could be perfor-
med in order to gain extra phenotypic information such as in the field of metabolomics and 
systems pharmacology. 
High-throughput small molecule profiling requires new approaches in sample preparation 
to allow fast DI-MS analysis. In summary, in this thesis first steps of new methods have been 
presented which are promising in small-molecule analysis using DI-MS. In Chapter 4 and 5 
new concepts regarding sample pretreatment have been developed. In general, the potential 
of both 3-phase EE and the described micro-LLE method might be improved when a derivati-
zation method can be integrated prior to extraction. By altering the physico-chemical proper-
ties of the relatively polar target molecules it might enable effective desalting and improved 
ionization efficiencies. 
Most of the methods presented in this thesis were integrated with direct infusion MS, as it is 
potentially the most suitable MS-based platform for comprehensive, high-throughput profi-
ling of small molecules. However, as described in Chapter 6, the small-volume yolk samples 
were analysed with LC-MS. Future research could be directed towards its coupling to DI-MS 
for which 3-phase EE might be a promising candidate since analytes can be purified and en-
riched in a small volume as described in Chapter 4. 
When the presented high-throughput concepts are further optimized, it is expected that these 
methods can be used in biomedical and pharmacological screening which eventually may 
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SAMENVATTING
In de gezondheidszorg wordt continu gestreefd naar verbetering en speelt kostenbesparing 
een steeds belangrijkere rol. Om de zorgkosten te beperken, is er een sterke behoefte aan 
zorginnovaties. Hierin zijn snellere en goedkopere analytische meetmethoden cruciaal. Het 
ultieme doel van deze nieuwe meetmethoden is het mogelijk maken van therapie op maat: 
‘personalized medicine’. Voor dit doel zijn er doorbraken nodig in biomedisch en farmaco-
logisch onderzoek. Het snelle fenotyperen van een biologisch systeem door middel van het 
globale profileren van kleine moleculen is hierin belangrijk.
Er is vaak een omgekeerd evenredig verband tussen de gevoeligheid (het aantal te detecte-
ren moleculen en molecuulklasses) en de snelheid en kosten van de meetmethode. Klassieke 
meetmethoden voor kleine moleculen, zoals bijvoorbeeld microscopie of immunoassays, 
analyseren voornamelijk een enkel molecuul met hoge meetsnelheid. Er is echter behoefte 
aan meer diepgaande meetmethoden waarbij vele kleine moleculen tegelijkertijd gemeten 
kunnen worden, met een acceptabele meetsnelheid. Tot dusver is het globale en tegelijkertijd 
snelle profileren van een breed scala aan kleine moleculen een uitdaging, vooral in het meta-
bolomics veld.
In dit proefschrift wordt de ontwikkeling van nieuwe methoden voor het snelle profileren 
van kleine moleculen in complexe biologische monsters, door middel van massaspectrome-
trie (MS) beschreven. Hiervoor is direkte infusie (DI)-MS een aangewezen, snelle techniek, 
omdat er voorafgaand aan MS detectie geen scheidingsmethode wordt gebruikt. Voor een 
succesvolle DI-MS meetmethode is het pre-analytische gedeelte een zeer belangrijke, maar 
tot dusver onderbelichte factor. De focus van dit proefschrift lag daarom op het ontwikkelen 
van nieuwe monstervoorbewerkingstechnieken waarbij, met betrekking tot de meetsnelheid, 
miniaturisatie en automatisering de rode draad waren.
Hoofdstuk 2 geeft een overzicht van de huidige monstervoorbewerkingstechnieken voor me-
tabolomics uitgevoerd met een MS.  Hoewel er op dit moment geen enkele universele mon-
stervoorbewerkingstechniek beschikbaar is voor de globale analyse van het gehele metabo-
loom, lijkt de combinatie van onteiwitten en het verwijderen van lipiden een goede strategie 
om een groter aantal metabolieten te meten en hun reproduceerbaarheid te verbeteren. Door 
recente ontwikkelingen op het gebied van geautomatiseerde off-line well-plate extractietech-
nieken (onteiwitting, vloeistof-vloeistof extractie en vaste-stof extractie) is een snelle mon-
stervoorbewerking al goed mogelijk. In de toekomst moeten monstervoorbewerkingstech-
nieken niet alleen geautomatiseerd en snel zijn, maar ook kwantitatief en gestandaardiseerd, 
zodat metabolomics data van verschillende studies uit verschillende labs vergeleken kunnen 
worden. Dit is vooral belangrijk voor metabolieten die deels gebonden kunnen zijn aan eiwit-
ten of andere factoren in bloed.
In Hoofdstuk 3 wordt de snelle fenotypering van zebravis embryogenese beschreven door 
middel van nanoelectrospray en hoge resolutie (HR) DI-MS. Met behulp van beperkte, maar 
efficiënte monstervoorbewerking werd gedemonstreerd dat gedetailleerde metabolietprofie-
len konden worden verkregen. Hierin konden vijf vroege ontwikkelingstadia met een tijds-
resolutie van slechts 1 uur  worden onderscheiden. Met behulp van gedegen dataverwerking 
werden 102 relevante moleculaire variabelen aangetoond. Deze variabelen weerspiegelen de 
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start van bepaalde genexpressie zoals bekend uit de literatuur en de toenemende energiebe-
hoefte. In de toekomst zijn effectievere en bij voorkeur snelle monstervoorbewerkingstech-
nieken wenselijk om nog meer (reproduceerbare) informatie te verkrijgen over metabolieten 
met een lage concentratie.
Uit de studie in Hoofdstuk 3 valt te concluderen dat met beperkte monstervoorbewerking en 
nanoelectrospray-DI-MS in combinatie met goede dataverwerking, gedetailleerde metabo-
lietprofielen van complexe monsters verkregen kunnen worden. Om de volledige potentie van 
DI-MS te benutten zouden er andere effectievere monstervoorbewerkingstechnieken moeten 
worden ontwikkeld (zoals bijvoorbeeld voorgesteld in Hoofdstuk 4 en 5) die bij voorkeur 
kleine polaire moleculen kunnen extraheren en scheiden van interfererende (endogene) zou-
ten, zoals gesuggereerd in Hoofdstuk 2.
In Hoofdstuk 4 wordt drie-fase elektroextractie (3-fase EE) naar een twee microliter druppel 
hangende aan een geleidende pipetpunt beschreven. Door middel van de elektromigratie van 
analieten in een waterige monsterfase met groter volume, door een niet-mengbare organische 
filter fase, naar een waterige acceptorfase met een klein volume, werd een snelle verrijking van 
carnitines gerealiseerd. De samenstelling van de organische filterfase bepaalde de selectiviteit 
van 3-fase EE. Deze eigenschap is niet alleen nuttig voor het afstemmen van de extractie van 
het aantal verschillende metabolieten naar keuze, maar ook om migratie van eiwitten naar de 
acceptordruppel te voorkomen. Hierdoor is 3-fase EE veelzijdig, omdat selectieve verrijking 
en tegelijkertijd purificatie van analieten in een enkele methode geïntegreerd worden. Ten-
slotte werd de potentie van 3-fase EE voor high-throughput screening gedemonstreerd, door 
een proof of principle van de online integratie van 3-fase EE in een commercieel en geautoma-
tiseerde nanoelectrospray-DI-MS platform.
Het aantal verschillende metabolieten dat met 3-fase EE  gemeten kan worden, kan in vervolg-
onderzoek worden uitgebreid door de samenstelling van de organische filterfase te optimali-
seren. Op deze manier zou 3-fase EE ook geschikt kunnen worden voor globale profilering. 
Bovendien valt het te voorzien dat 3-fase EE ontzoutings eigenschappen kan hebben vanwege 
de organische filter fase, hoewel dit niet is aangetoond in dit proefschrift. Verder zou de ver-
rijkingsfactor verbeterd kunnen worden door de dimensies van 3-fase EE te optimaliseren. 
Ook zouden er in de toekomst microfluïdische chiptechnologieën ingezet kunnen worden om 
3-fase EE verder te miniaturiseren. Hierbij kan de potentie van massief-parallelisatie (in het 
kader van high-throughput screening) verder verkend worden.
In Hoofdstuk 5 wordt een geminiaturiseerde vloeistof-vloeistof extractie beschreven, door 
middel van gasdruk-geassisteerd mengen, gevolgd door passieve fasescheiding. Deze metho-
de zorgde ervoor dat de gehele extractieprocedure uitgevoerd kon worden in een 384-well 
plaat, geïntegreerd in een commerciële en geautomatiseerde nanoESI-DI-MS robot. Door 
de gasdruk en tijdsduur te variëren kon de effectiviteit van het mengproces geoptimaliseerd 
worden. Voor de extractie van geneesmiddelen uit menselijk plasma toonde dit platform, in 
vergelijking met een conventionele, manuele vloeistof-vloeistof extractie procedure, goede 
analytische eigenschappen met betrekking tot precisie en lineariteit. De resultaten demon-
streerden de potentie van dit nieuwe volledig geautomatiseerde platform voor de analyse van 
geneesmiddelen in complexe (klein-volume) monsters zoals plasma en gedroogde bloedspots.
De dichloormethaan fase is na vloeistof-vloeistof extractie succesvol geanalyseerd met nanoe-
lectrospray-DI-MS. Hierdoor is onze methode zeer geschikt voor de analyse van relatief apo-
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beide fases geïnfuseerd worden na extractie. Dit kan interessant zijn voor de de analyse van 
polaire verbindingen in de (opgeschoonde) waterige fase. Wel moet dan rekening gehouden 
worden met een mogelijk hoge concentratie van (endogene) zouten in de waterige fase en zou 
een additionele verdunningsstap nodig kunnen zijn.
 
Tot slot wordt in Hoofdstuk 6 een geminiaturiseerde samplingmethode beschreven waarbij 
met behulp van een micronaald de opname van geneesmiddelen in de (klein-volume) dooier 
van zebravislarven gemonitord wordt met massaspectrometrie. Eerst werd aangetoond dat de 
huidige methoden door middel van gehele embryo lyse geen rekening houden met mogelijk 
adsorptie van geneesmiddelen aan de huid. Dit kan resulteren in vals-positieve opnameuit-
komsten. Onze micronaaldmethode biedt wèl de mogelijk om de opname van in principe elke 
nieuwe verbinding in de zebravis correct te monitoren. Dit is erg belangrijk omdat geen en-
kele physisch-chemische eigenschap gebruikt kan worden om de opname van de verbinding 
in de zebravis accuraat genoeg te voorspellen. Met onze methode werd de opname van 15 
pre-klinische verbindingen en twee veel gebruikte anti-tuberculosis geneesmiddelen gemo-
nitord en gecorreleerd aan high-throughput screening data van M. Marinum geïnfecteerde 
zebravislarven en aan andere conventionele in vivo en in vitro modellen. Met ons verbeterde 
zebravis geneesmiddel-screening platform kunnnen nieuwe inzichten verkregen worden in 
de interpretatie en voorspelling van de effectiviteit van een geneesmiddel.
Het ligt in de lijn der verwachting dat deze methode een deur opent voor het gebruik van ze-
bravislarven in gedetailleerde farmacologische bepaling van aktiviteit (zoals PK modellering) 
en dat het een bredere acceptatie van de zebravis in het ontdekken en ontwikkelen van nieuwe 
geneesmiddelen teweegbrengt. Ook zou er naast de gerichte analyse van geneesmiddelen uit 
het microsample een globale profilering van kleine moleculen uitgevoerd kunnen worden, 
waarbij men extra informatie over het fenotype krijgt met betrekking tot metabolomics en 
systeemfarmacologie.
De profilering van kleine moleculen vereist nieuwe monstervoorbewerkingstechnieken om 
snelle DI-MS analyses mogelijk te maken. Samenvattend werden in dit proefschrift de eerste 
stappen gezet voor nieuwe methoden die veelbelovend zijn in de analyses van kleine mole-
culen met DI-MS. In Hoofdstuk 4 en 5 werden nieuwe concepten met betrekking tot mon-
stervoorbewerking gepresenteerd. In het algemeen zou de potentie van zowel 3-fase EE, als 
de micro vloeistof-vloeistof-extractie methode beter benut kunnen worden wanneer alvorens 
extractie een derivatiseringsmethode geïntegreerd wordt. Door de physisch-chemische eigen-
schappen van relatief polaire verbindingen gunstig te veranderen zijn effectieve ontzouting en 
verbeterde ionizatie efficiëncies mogelijk.
De meeste methoden in dit proefschrift werden geïntegreerd met DI-MS, omdat deze MS-
techniek in potentie erg geschikt is voor het globale en snelle profileren van een groot aantal 
kleine moleculen. In Hoofdstuk 6 werden de (klein-volume) dooiermonsters echter geana-
lyseerd met vloeistof-chromatografie-MS. In vervolgonderzoek zou de koppeling met DI-MS 
onderzocht kunnen worden, waarbij 3-fase EE wellicht een goede monstervoorbewerkings-
techniek is, omdat analieten hierbij verrijkt en gepurificeerd kunnen worden, zoals beschre-
ven in Hoofdstuk 4.
Wanneer de gepresenteerde high-throughput concepten verder uitgewerkt en geoptimali-
seerd worden, zouden deze methoden gebruikt kunnen worden in biomedische en farma-
cologische screeningstoepassingen. Dit kan uiteindelijk bijdragen aan de ontwikkeling van 
‘personalized medicine’.
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